KERALA MEDICAL SERVICES CORPORATION LIMITED

(A Government of Kerala Undertaking)

Thycaud P.O, Thiruvananthapuram, KERALA 695 014

INVITATION OF EXPRESSION OF INTEREST

for

EMPANELMENT OF DRUGS TESTING LABORATORIES

EOI No: KMSCL/QC/EOI/2016/01 dated 05.10.2016

Name of EOI Responder:

Address:

Last date and time for the receipt of EOI Response: **04.11.2016. 02.30pm**

For details;

www.kmscl.kerala.gov.in

Email: **kmsclqc@gmail.com**

Table of Contents

SECTION I
INVITATION OF EXPRESSION OF INTEREST

1.1 The Kerala Medical Services Corporation Limited - hereinafter mentioned in this document as KMSCL or the Corporation - is a fully owned Government of Kerala company set up in 2007 for providing services to the various health care institutions under the Department of Family Welfare and Health. One of the key objectives of the KMSCL is to act as the central procurement agency for all essential drugs, other consumables and equipments for all health care institutions under the above said Department.

1.2 The Corporation invites applications in the form of Expression of Interest - EOI in short- for Empanelment of Drugs Testing Laboratories for the Analysis of Drugs, Medical Devices, Supplies, Surgical Sutures etc more specifically mentioned in Appendix for a period of two years from the Date of Acceptance. The Managing Director of the Corporation is the Expression of Interest Inviting Authority for this purpose.

1.3 Laboratories which are willing to undertake complete testing and analysis of the drugs, other medical supplies and consumables at the rates prescribed in the Appendix I-A and offer rates for complete testing of the items in Appendix I-B and willing to accept the terms and conditions as prescribed under the EOI document are eligible to be selected as the "Empanelled Drugs Testing Laboratory of KMSCL".

1.4 The rates specified for the test/ analysis in this document are the final rates, that include all costs of chemicals, reagents, other supplies and consumables, capital investments in equipments, infrastructure, and all overheads for performing tests/ analysis as per the standards applicable analysis and for furnishing test reports together with all relevant protocols to KMSCL. The offerers shall be willing to undertake the tests/analysis subscribing to terms and conditions of this EOI document at these pre-fixed rates.

1.5 Performance of the tests/analysis strictly in accordance with the official/ recognized parameters of standards and delivery of test/ analysis reports in time and consistency of the analysis results are the most important factors to be adhered to by the Empanelled Laboratories.

1.6 The period of contract shall be two years from the date specified in the agreement to be executed for the purpose of the contract. The EOI Offerer shall give firmness of the rate prescribed and agreed upon for a period of two years from the date of agreement.

SECTION II

EOI SCHEDULE

2.1 **Important details of the EOI:**

1.	*EOI No.*	**KMSCL/QC/EOI/2016/01**
2.	*Cost of EOI Document*	**Rs.1000/-**
3.	*Earnest Money Deposit*	Rs.25,000/- (refundable)
4.	*Form of Earnest Money Deposit*	Demand Draft
5.	*Validity of EMD*	180 days from the date of opening of technical document
6.	*Performance Security Deposit*	Rs.50,000/-
7.	*Validity of Performance Security deposit*	30 months from the date of execution of agreement

2.2 **Important Dates:**

Sl.No	Particulars	Date and time	Venue
1.	*Date and time of commencement of sale of EOI document*	**05.10.2016 2.30pm**	**Head Office, KMSCL.**
2.	*Date and time of Pre- offer meeting*	**21.10.2016. 11am**	
3.	*Last date and time of receipt of offers*	**04.11.2016. 2.30 pm**	
4.	*Date and time of opening of the offers*	**04.11.2016. 3.00 pm**	

SECTION – III
SPECIFIC CONDITIONS OF EOI

3.1 **Time Limits:**

The Empanelled Drug testing Laboratories shall furnish test reports at the Corporation with in the time limit specified below:			
Category	**Permitted from the date of receipt of sample**	**Penalty for delayed reporting**	
		Step -I	**Step –II***
All non-sterile preparations	15 days	@ 0.5% per day of the delayed reporting upto a max of 15% (30 days) Note-from 16th to 45th day.	@ 1% /day of the delayed reporting upto a max of 45% (30 days) Note- from 46th to 75th day
All sterile preparations	30 days	@ 0.5% /day of the delayed reporting upto a max of 15% (30 days) Note -from 31st to 60th day	@ 1% /day of the delayed reporting upto a max of 45% (30 days) Note-from 61st to 90th day

Note: 1. *The time period shall be calculated from the date noted in the proof of delivery (POD) submitted by the couriers, which shall be binding on the empanelled lab.*

2. *if further delay occur in submitting of that particular test report for more than the following days* that particular test reports will be rejected and action will be taken as per clause 4.9.15.*

** i. Non- Sterile Preparations :- 75 days (ie: 15+30+30)*

**ii. Sterile Preparations:- 90days (ie: 30+30+30)*

3.1.1 If any of the test reports are cancelled/rejected due to delay, the expenditure and other losses sustained in the process, shall be recovered from the Security Deposit or performance guarantee or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier.

3.2 **Prequalification Criteria:**

3.2.1 The Laboratory presenting the EOI (Offerer) shall have valid Approval under the Drugs and Cosmetics Rules, 1945, valid Good Laboratory Practices (GLP) certificate issued by the competent authority under the Drugs and Cosmetics Rules and with valid NABL accreditation. No EOI shall be presented in respect of any drug or any other item in respect of which such approval/ certificate/accreditation is not possessed by the Offerer.

3.2.2 The Offerer should have standing in the field of testing and analysis of drugs/ consumables & other supplies in respect of which the EOI has been made for the last three years.

3.2.3 The Offerer shall have an average annual turnover of not less than Rs. 25 lakhs (Twenty five lakhs) for the last three consecutive years .i.e., 2012-2013, 2013-2014 and 2014-2015.

3.2.4 The Offerer shall be a stand-alone laboratory i.e independent and not an in-house facility part of a manufacturing unit.

3.2.5 The Offerer should have undertaken analysis of drugs and supplies of similar nature for at least three Government departments/ institutions / reputed manufacturers of drugs & supplies during the last three years.

3.2.6 The Offerer should be one located anywhere in India and should not have been blacklisted by KMSCL during the period of blacklisting or blacklisted/ debarred by any other State / Central Government's organization or one whose approval had been suspended or revoked partially or in full by any statutory authority during the period of blacklisting.

3.2.7. The facilities availed/ offered for test/ analysis of drugs and other items shall be own and located in the premises in respect of which the EOI is made. Performance of tests/analysis partly in one place and partly in another place or fully in a place other than the one in respect of which the EOI is made will not be acceptable.

SECTION-IV

GENERAL CONDITIONS OF CONTRACT

4.1 EOI Document

4.1.1 The terms and conditions governing the Empanelment of laboratories are contained in this "EOI Document". The document can be downloaded from website **www.kmscl.kerala.gov.in.**

4.1.2 Failure to furnish any information/ document as required in this EOI document and submission of an offer not substantially responsive to it in every respect shall be at the Offerer's risk and would result in the rejection of the offer, without any notice.

4.1.3 It is mandatory to provide a check list as per Annexure I as the facing sheet for the EOI offer submitted so as to enable the Corporation to prima facie verify the compliance of submission of requisite documents at the time of opening of EOI. Failure to furnish the check list would make the offer deemed as non-responsive and open for summary rejection.

4.1.4 Language of EOI and other communications and signatories thereof: - The EOI submitted, all documents accompanying it presented thereof and all communications between the Offerer and the EOI Inviting Authority shall be in English language. Supporting documents in originals or copies as the case may be, issued by a statutory authority or court and furnished by the Offerer for the purposes of this EOI or for any purpose after empanelment, may in any other Indian language provided they are accompanied authenticated accurate translation of the relevant passages in the English language in which case, for purposes of interpretation of the offers, the English translation shall govern. Any communication from the Corporation made by an officer of the Corporation not below the rank of Quality Control Manager on behalf of the Managing Director shall be deemed as a communication by the EOI Inviting Authority and any communication/ correspondences made or any paper signed by an Authorized Signatory or (Specific) Power of Attorney (POA) Holder for the purposes of this EOI shall be deemed as communication/ correspondence made by the Offerer provided such POA has been presented along with the EOI in such manner as specified.

4.1.5 The EOI and accompanying documents once submitted shall not be altered in manner and should not have any scope of ambiguity, cutting, pasting, overwriting, masking, alteration etc. Modification of the offer, of the nature and to the extent provided in this document prior to the time and date set for

submission will, however, be entertained. Any overwriting / cutting/ correction otherwise of inadvertent error in the EOI made before its presentation it must be one authenticated with signature of the Offerer in full and such modifications as above that are not duly authenticated would necessitate summary rejection of the EOI. No such correction or modification as above in the accompanying document will be considered and documents with corrections would make the EOI defective/ non-responsive.

4.1.6 The documentary evidences submitted along with the EOI shall be produced duly attested by the Offerer on every page and serially numbered.

4.1.7 A copy of the complete EOI document duly signed on every page by the Offerer or the authorized representative shall be enclosed as part of the EOI as a proof of having read and accepted the terms and conditions of the EOI document.

4.1.8 The EOI shall be a computer typed one and signed by the Offerer or person(s) duly authorized to bind the Offerer to the Contract with Corporation. The person signing the documents shall have due Power of Attorney made by the Board of Directors/Partnership/Proprietor/Society/ Trust etc in cases where person other than the Managing Director/Managing Partner/ President or Chairman of the Society/ Trust etc or sole Proprietor signs the document. The photo of the person authorized to sign the document shall be affixed to the Power of Attorney with due authentication. Where the Managing Director/Managing Partner or other such person as mentioned above or the sole Proprietor signs the EOI and accompanying documents a notarized document attesting the signature of the person shall be furnished. The Power of Attorney shall be in non-judicial stamp paper duly notarized.

4.1.9 An offer submitted in vague/ ambiguous terms and the like, shall be termed as non-responsive and shall be summarily rejected.

4.1.10 At any time prior to the dead line for submission of the EOI, the EOI Inviting Authority may, for any reason, modify the EOI document by amendment. The amendment will be published in the website of the Corporation and shall be binding all prospective Offerers.

4.1.11 Pre-offer meeting will be held by the Corporation to explain briefly about the requirements as well as the terms and conditions of the EOI document and to get the views of the prospective Offerers, as part of ensuring transparency in the EOI process. Failure to attend the pre-offer meeting will not be a disqualification, but will be a loss of opportunity for the prospective Offerer to understand the EOI terms & conditions. Date of pre-offer meeting is

mentioned in Section II. Filled up EOI will be accepted only after the date of pre offer meeting.

4.1.12 The EOI shall remain firm and valid for two years. An offer for a shorter period shall be rejected by the Corporation as non-responsive.

4.1.13 The EOI shall be sent in sealed envelope by registered post or by courier to the following address:

The Managing Director
Kerala Medical Services Corporation Ltd
Thycaud P.O, Thiruvananthapuram -14.
Kerala– 695014.

Phone No: 0471- 2337353, 3045600
e-mail: kmsclqc@gmail.com

4.1.14 The envelope containing the EOI document is to be super scribed with the title **"EXPRESSION OF INTEREST FOR EMPANELMENT OF DRUGS TESTING LABORATORIES No KMSCL/QC/EOI/2016/01 DATED 05.10.2016 FOR THE YEAR 2017-19"**

4.1.15 EOI sent by telex or fax or email is void. The EOI may be presented in person also in sealed envelope, addressed and superscribed as above before the time and date specified.

4.1.16 If the EOI is sent by Registered post or by Courier, it should reach the above office on or before the time and date stipulated in Section II. The Corporation shall not be held liable for the delay in transit.

4.1.17 The Offerer may modify or withdraw its offer, after the EOI submission, provided that written notice of the modification or withdrawal is received by the Corporation before the date of opening of the EOI. The Offerer's modification or withdrawal notice shall be signed by the Offerer or his / her authorized representative, who have signed the original EOI documents. A withdrawal notice may also be sent by fax or email but should necessarily be followed by a signed confirmation copy to be received at the head office of the Corporation before the date of opening of the technical document.

4.2 Earnest Money Deposit (EMD):

4.2.1 The EOI shall be accompanied by the EMD as prescribed. Non-submission of sufficient EMD as mentioned in Section II along with the Technical document shall result in summary rejection of the EOI.

4.2.2 The EMD shall be in the form of demand draft drawn in favour of Managing Director, Kerala Medical Services Corporation Limited, payable at Thiruvananthapuram.

4.2.3 Cheque, Cash payment, Money Order, Fixed deposit, Bank Guarantee etc will not be accepted as EMD and in such cases the EOI offer will be rejected.

4.2.4 Laboratories fully owned by the Government / PSUs and reputed Research & Development Laboratories attached to scientific / research institutions are exempted from remittance of EMD subject to submission of valid documents.

4.2.5 EMD of unsuccessful offerers will be discharged / returned as soon as possible within thirty days after publishing of the final list of successful EOIs by the Corporation.

4.2.6 The successful Offerers' EMD will be discharged upon the Offerer signing the contract and furnishing the performance security. The EMD of the successful Offerer may be adjusted towards the performance security payable.

4.2.7 No interest will be paid for the EMD.

4.2.8 The EMD will be forfeited, if an Offerer;

4.2.8.1 Misrepresents facts or submit false / fake documents during the EOI process.

4.2.8.2 If the Offerer willfully violates any terms and conditions of the EOI documents.

4.2.8.3 If the Offerer withdraws its bid after the opening of EOI document.

4.2.8.4 A successful Offerer fails to sign the contract after issuance of Letter Of Intent.

4.2.8.5. If the EOI offer is rejected on the basis of the non satisfactory inspection report of the Quality control facilities of the firm.

4.3 Empanelment policy :

4.3.1 The list of drugs/supplies for which rates to be finalized for complete Laboratory testing are attached as Appendix I-A & I-B.

i) <u>Appendix I-A</u>

The final rate for testing of samples of each item is pre-fixed and are mentioned in column 7 of Appendix I-A. The Laboratories interested to perform the tests for the items at these rates can make offer for that item in the format specified in Annexure-VII (Consent letter of the Offerer).

ii) <u>Appendix I-B</u>

The rates for testing of the items in this list are not fixed. **The Testing Laboratories can offer the rates at which the complete testing of the items are performed and the rate for testing shall be filled by the Offerer in column 7 in**

Appendix I-B in the format specified in Annexure-VII (Consent letter of the Offerer)**.** The offered rates shall be inclusive of cost of chemicals, reagents, other consumables, cost and depreciation of value of equipments, infrastructure, labour charges, other overheads and expenses and incidentals to the furnishing of reports and other charges such as statutory taxes and levies. The EOI offering minimum rate for testing will be selected for testing that item.

4.3.2 The EOI Inviting Authority has every right to fix the final testing rate of item comparing with the testing rates for similar products, rates offered by other labs etc.

4.3.3 The EOI Inviting Authority will publish the final testing rate(s) of items in Appendix I-B in the website of the Corporation permitting the other qualified laboratories to match with the final testing rate(s). The Corporation will empanel such laboratories also who have given the consent in writing for testing the items in the final rate(s).

4.4 Contents of the EOI documents:

4.4.1 The EOI must be accompanied by the following documents in the sealed cover submitted. The documents shall be in the format prescribed.

	Documents to be submitted	Format prescribed
1.	Checklist (Annexure –I) for the EOI and the list of documents enclosed, with their page numbers marked. The EOI and the documents should be serially numbered and arranged as per Annexure–I. The page number(s) of each document shall be shown in the checklist.	PDF format in DVD & Hard Copy
2.	The Earnest Money Deposit, IF NOT EXEMPTED, shall be Rs. 25,000/-. The Earnest Money Deposit shall be paid in the form of Demand Draft favouring Managing Director, Kerala Medical Services Corporation Limited, payable at Thiruvananthapuram. IF EXEMPTED as per clause 4.2.4 valid documentary evidence to prove the claim shall be furnished.	Hard Copy

3.	Copy of notarized Documentary evidence for the constitution of the company /concern such as Memorandum and Articles of Association, list of names and addresses of the Directors, along with notary attested copies of Form 32 whenever there is a change of Directors, current Partnership deed (Notary attested copy) etc, Name and address of the Chairman/ President/ Managing Trustee, Secretary etc in the case of societies, trusts etc details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of such Managing Director / Partners / Proprietor/ others responsible for the conduct of business and operation of the laboratory.	PDF format in DVD & Hard Copy
4.	Annual turnover statement (Original) certified by the auditors for last three years i.e., 2012-13, 2013-2014 & 2014-15 as in Annexure-V	PDF format in DVD & Hard Copy
5.	Notary Attested Photocopy of approval for testing of Drugs and the list of drugs approved for testing in the laboratory issued by the Drugs Control Authority and valid renewal with list of approved products for testing.	PDF format in DVD & Hard Copy
6.	Notary Attested Photocopy of valid GLP Certificate issued by the Drugs Control Authority and valid renewal.	PDF format in DVD & Hard Copy
7.	Notary Attested Photocopy of NABL accreditation certificate and its valid renewal.	PDF format in DVD & Hard Copy
8.	Service Tax Clearance Certificate issued by the concerned authority and attested copy of certificate of registration for service tax.	PDF format in DVD & Hard Copy
9.	Notary attested copies of audited Balance Sheet and Profit and Loss account for the last three years i.e. 2012-13, 2013-14 & 2014-15.	PDF format in DVD & Hard

		Copy
10	The list of qualified personnel employed in the laboratory (Employees name, Qualification and experience)	PDF format in DVD & Hard Copy
11.	The list of sophisticated analytical equipments & apparatus available in the laboratory as in Annexure III	PDF format in DVD & Hard Copy
12.	Duly filled performance statement in Annexure IV	PDF format in DVD & Hard Copy
13.	Declaration in the Proforma given in Annexure-VI duly signed and notarized	PDF format in DVD & Hard Copy
14.	Details of Analytical Laboratory in Annexure–II	PDF format in DVD & Hard Copy
15.	Consent letter of the offerer as in Annexure VII, giving the details of the Drug / items offered to be tested in compliance with the EOI conditions and the consent for testing the Drugs / items at the rates offered in Appendix I-A & I-B.	DVD in **.xl** format & Hard Copy
16.	EOI document signed by the offerer in all pages with office seal	Hard Copy
17.	Notary attested copy of PAN.	PDF format in DVD & Hard Copy

4.5 Evaluation of EOI:

4.5.1 The opening of the EOI offer will be done by the Corporation in the presence of the Offerers or their representatives who choose to attend at the respective time and place mentioned in Section II.

4.5.2 In the event of the specified date for EOI submission/opening being declared holiday, the EOI submission/opening shall be at the appointed time and venue on the next working day.

4.5.3 The Offerer shall be responsible for properly superscribing and sealing the envelopes and the Corporation shall not be liable for inadvertent opening of the envelopes before the time appointed for opening of the offers.

4.5.4 The documents submitted as part of the offer shall be scrutinized by Committee constituted by the EOI Inviting Authority.

4.5.5 An EOI, at any stage of the evaluation process or thereafter, in the event of being found concealment or misrepresentation of facts, in respect of the claims of the offer, shall be rejected and is liable to be black listed for a period as decided by the EOI Inviting Authority.

4.5.6 The Corporation may waive any minor infirmity in an offer, which does not constitute a material deviation, provided that the same shall not prejudicially affect the interest of the other Offerers.

4.5.7 No EOI may be withdrawn in the interval after the opening and finalization of the EOIs. Withdrawal of an EOI during this interval will result in the forfeiture of its EMD and black listing of the Offerer for a period of 3 years immediately from the date of such order and the Offerer shall be ineligible to participate in any of the offers / tenders of the Corporation for a period of 3 years.

4.6 Inspection of Testing Facilities of the Laboratory:

4.6.1 Inspection of the testing facilities will be at the discretion of the EOI Inviting Authority. Such inspection may be at any stage before or after acceptance of the offer or Award of Contract/ empanelment.

4.6.2 All the testing facilities in the lab will be subjected to inspection / auditing, irrespective of the items in respect of which the EOI has been made/offered. i.e. if the Offerer has offered testing of only for tablets but is having the testing facilities of Injectables / Liquids / etc. all the sections will be subjected to inspection. The Offerer will have to provide necessary arrangements to conduct the inspection of all the sections and failure to co-operate with the inspection in showing the different facilities, will lead to disqualification. Entry to all the areas of testing including microbiological section of the lab shall be facilitated.

4.6.3 During inspection undue demands, demands beyond the scope of the this EOI etc made by the members of the Inspection team shall be immediately notified to the EOI Inviting Authority by the laboratory by fax/email, so that the disputes could be resolved before the Inspection Team left the laboratory. The recommendations of the Inspection team will not be communicated to the Offerer at their site and shall be published on the later only. A summary of findings without stating the recommendations/ conclusions may, however, be furnished to the laboratory soon after the inspection.

4.6.4 The availability of technical experts, analytical facilities as claimed in the EOI offer along with the compliance of standard operating procedures adapted for each procedure including validation and calibration, shall be evaluated by the team for considering the eligibility of the lab. Claims of holding the valid NABL certification/valid approval/ GLP certificate will not be of any avail, if the procedures prescribed are not followed as per the standard operating procedures or if the available facilities are not in proper conditions or if contraventions of GLP norms are observed at the time of inspection. In the event of failure to facilitate inspection, obstruction to carry out the inspection, non-cooperation during the inspection, failure furnish any record needed for verification etc., the EOI offer will be rejected or agreement will be terminated, as the case may be.

4.6.5 The minimum number of samples that could be tested at a time will be one of the criteria for determining the acceptance/rejection of the lab. The Inspection team shall also verify the capability of the Offerer in fulfilling the requirement of the Corporation.

4.6.6 Copy of one full set of the EOI offer should be made available at the time of inspection.

4.6.7 Originals of all the documents submitted in the EOI offer should be produced for verification by the inspection team. Failure to produce any of the original documents will result in the rejection of the offer.

4.6.8 Key testing areas will be photographed by the inspection team. Denial of permission for photographing will result in the rejection of EOI offer.

4.6.9 Any of the Laboratories during the inspection, found not complying with the requirements, the offer of the firm will be rejected/agreement will be terminated. An inspection fee of Rs. 25,000/- will be deducted from the EMD/SD/any money due to the firm.

4.7 Acceptance / Rejection of offers:

4.7.1 Acceptance /rejection of the EOI offer will be based on the decisions taken on the evaluation of the submitted documents and inspection report from the expert committee.

4.7.2 At any point of time before or after the award of contract, the EOI Inviting Authority reserves the right to cancel or modify the contract in respect all or any of the items of drugs or other consumables in respect of an EOI for breach of the terms and conditions of the EOI or of the agreement thereof.

4.7.3 The EOI Inviting Authority, or his authorized representative(s) has the right to inspect the labs of Offerers, before releasing any samples or at any point of time during the continuance of offer and also has the right to reject the offer or terminate / cancel the contract awarded and or to re-test, based on adverse reports brought out during such inspections. Retesting of samples may also be done by the EOI Inviting Authority at any stage before or during the operation of the contract, to evaluate the performance of the laboratory and the EOI Inviting Authority may initiate deterrent or punitive measures if the evaluation processes or the inspections so indicate or necessitate.

4.8 Award of Contract:

4.8.1 The Corporation will notify the successful Offerer (s) in writing, by registered / speed post or by email that its/ their offer(s) for testing of drug(s)/ other items, which have been selected by the EOI Inviting Authority, has been accepted. This notification is made by issuing a **Letter of Intent** by the EOI Inviting Authority.

4.8.2 The successful Offerer, upon receipt of the Letter of Intent, shall execute an agreement in the format prescribed, in a non-judicial Kerala Stamp paper of value of Rs. 200/- or of such revised value as may be notified by the Government (stamp duty to be paid by the Offerer) within 15 days from the date of the intimation from Corporation that his offer has been accepted. The Specimen format of agreement is available in Annexure-IX.

4.8.3 There will be a performance security deposit amounting to Rs 50,000/- (Rs. Fifty Thousand only) which shall be submitted by the successful Offerer along with the agreement within 15 days from the date of issuance of Letter Of Intent, in the form of Demand Draft drawn in favour of the Managing Director, Kerala Medical Services Corporation Limited payable at Thiruvananthapuram/ Bank Guarantee in the format as given in Annexure VIII for a period of 30 months from the date of execution of the agreement.

4.8.4 If the successful Offerer fails to execute the agreement and / or to deposit the required performance security deposit within the time specified or withdraws his offer after opening of the bid, his award of contract will be cancelled and the Earnest Money Deposit of the firm shall stand forfeited, Corporation will initiate blacklisting process and the laboratory shall also be blacklisted for a period of three years immediately from the date of such order and the Offerer will be ineligible to participate in any of the offers/EOI processes of the Corporation for a period of three years.

4.8.5 The Offerer shall not, at any time, assign, sub-let or make over the contract or the benefit in full or part thereof to any person or persons what so ever.

4.8.6 For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the EOI Inviting Authority, and the Offerer shall be liable for all losses sustained by the EOI Inviting Authority, in consequence of the termination which may be recovered personally from the Offerer or from his properties, as the case may be.

4.8.7 All notices or communications relating to arising out of this EOI/agreement or any of the terms there of shall be considered duly served on or given to the Offerer if delivered to him or left at the premises, places of business or abode. Any notice or other communication sent by e-mail or by any other electronic mode shall also be deemed to be due service of the notice/ communication.

4.8.8 In the event of any failure/blacklist/default/deviations from the terms and conditions of the EOI or the agreement thereof, of the successful tenderer with or without any quantifiable loss to the EOI Inviting Authority, the amount of the performance security is liable to be forfeited.

4.8.9 The EOI Inviting Authority will release the Performance Security without any interest to the successful Offerer on completion of all contractual obligations.

4.8.10 If the successful Offerer withdraws from the contract during the period of contract, his security deposit will be forfeited, the contract will be terminated, Corporation will initiate blacklisting process and the laboratory will be blacklisted for a period of three years immediately from the date of such order making them ineligible to participate in any of the offers / Tender of the Corporation.

4.9 Testing & Reporting Conditions:

4.9.1 On empanelment and entrustment of the job, the Analytical Laboratory shall furnish the test reports within.

1. 15 days of receipt of the sample in case of all non-sterile Preparations.
2. 30 days of receipt of the sample in the case of sterile preparations.

4.9.2 All the tests mentioned in IP/ BP/ USP/ BIS/In-house test procedure/Drugs & Cosmetics Rules. etc., (as the case may be) should be carried out for each and every sample. The actual test value obtained after analysis should be clearly mentioned in the report figures/& words in the report of test/ analysis. Amendments, Addendum, Corrigendum etc published to the reference monographs shall be taken in to account in the testing parameters time to time.

4.9.3 Mentioning the words, "COMPLIES" or "PASSES" in the result column of the report shall be treated as incomplete report. It is essential to express the value of test results in figures and the value of standard limits.

4.9.4 **Test report should be submitted as per Form 39 of D&C Act and additional details should be given as prescribed in Annexure X. Every test report must have remarks (i.e.) Standard Quality or Not of Standard Quality with respect to protocol applied.**

4.9.5 Reports should be in A4 size paper of good quality.

4.9.6 Reports should have Sl.No., Description of tests, Specifications, Results obtained and the reference monograph and NABL accreditation number and its validity,

4.9.7 Protocols of test applied shall be furnished along with the test report. Spectra /Chromatography data sheets, where ever applicable shall also be furnished.

4.9.8 All test reports should be submitted to the KMSCL in triplicate. In case of failure of a sample, the result should be communicated immediately to the Managing Director through Phone/Fax/E-mail and the report should be sent with protocol.

4.9.9 If under any circumstances (like break down of instrument, non availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for samples, the same should be reported within 24 hours of receipt of such samples by FAX or E-mail and the samples should be returned to the Quality Control Section, Kerala Medical Services Corporation Limited, Thiruvananthapuram. Return of samples under false claims of mal-functioning of equipment/ break-down of systems etc will be deemed as fraudulent practices and the contract will be liable to be terminated and the laboratory be black-listed without prejudice to criminal proceedings for breach of trust and other such offences.

4.9.10 Every care will be taken for proper packaging of the sample to ensure safe and intact delivery to the laboratory. If, however, any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the Quality Control Section, Kerala Medical Services Corporation Limited, Thiruvananthapuram by FAX or E-mail. Deliberate attempt to damage or damaging of the package after receipt shall amount to fraudulent practice leading to termination of contract, black-listing and criminal proceeding for breach of trust, contract etc.

4.9.11 In the case of Non-Pharmacopoeial Products the Method of Analysis should be appended to the Report.

4.9.12 Test Results shall be sent through e-mail to kmsclqcresults@gmail.com followed by signed hardcopies and with authorized persons name & signature.

4.9.13 Furnishing of incomplete/inconsistent/ incorrect/ unreliable test results for three times or more during the contract will lead to the termination of contract of the laboratory. Corporation will initiate blacklisting process and the lab will be blacklisted for a period of three years immediately from the date of such order and the Offerer will be ineligible to participate in any of the offers/tenders of the Corporation for a period of three years.

4.9.14 If submitted test reports is found to be incomplete/inconsistent/incorrect/ unreliable, those test reports will not be consider as test reports and the payment regarding the same will be forfeited.

4.9.15 Furnishing of three or more delayed test reports occurred during the contract, such practices will considered as default reporting and its lead to the termination of contract. Corporation will initiate blacklisting process and lab will be blacklisted for a period of three years from the date of such order making them ineligible to participate in any of the offers / Tender of the Corporation.

4.9.16 Any change/replacement of the authorized person/persons who is responsible for the signing of the test report should be intimated to the Corporation within 15 days. If no intimation received from the Laboratory, it will be considered as fraudulent practice and will initiate blacklisting process.

4.10 Payment Provisions:

4.10.1 No advance payments towards Analysis of drugs will be made.

4.10.2 Payments towards the Analysis of drugs will be made strictly as per terms and conditions laid down in the EOI document and the decisions of the EOI Inviting Authority. All payments will be made only by way of electronic fund transfer in favour of the laboratory.

4.10.3 All bills / Invoices in triplicate is to be submitted directly to the Headquarters.

4.10.4 If at any time during the period of contract, the testing fee of any items is reduced by the Offerer himself or the taxes levied is brought down by any law or Act of the Central or State Government the Offerer shall be bound to inform Corporation immediately about such reduction in the contracted prices. The EOI Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Offerer fails to notify or fails to agree for such reduction of rates.

4.10.5 The Offerer shall be responsible for payment of any charges due to any statutory authorities such as Income Tax, Sales Tax, Service tax, and Customs Duties etc. In the event, if it is found that there is some statutory deduction to be made at the source, the Corporation will have the authority to do so.

4.10.6 If, at any time during the operation of the contract, any new/ additional statutory tax or other levy is imposed to the testing of the drugs and other items or if the statutory taxes, levies, duties etc applicable are increased, the rates agreed upon for testing will also be eligible to be increased proportionally.

4.11 Saving Clause:

4.11.1 No suit, prosecution or any legal proceedings shall lie against Corporation or any person for anything that is done in good faith or intended to be done in pursuance of tender.

4.12 Applicable Law & Jurisdiction of Courts:

4.12.1 The contract shall be governed by and interpreted in accordance with the laws of India for the time being in force.

4.12.2 Any and all disputes arising out of this EOI will be subject only to the jurisdiction of courts of law / tribunals situated in Thiruvananthapuram city or normally having territorial jurisdiction over Thiruvananthapuram city only or the High Court of Kerala as applicable. It is possible that jurisdiction to file disputes may available before courts of law, including High Courts / Tribunals situated elsewhere. However, the Offerers should specifically agree and covenant not to file any legal proceedings before any such courts of law / tribunal and should undertake and bind themselves to initiate and carry on legal proceedings in respect of this EOI exclusively before the Courts of law /Tribunals situated in or normally having territorial jurisdiction over Thiruvananthapuram city, or the High Court of Kerala as applicable. Any offerer who violates these conditions will be held to have indulged in an unacceptable / unfair practice and will be deemed ineligible to participate in any of the offers/tenders of the Corporation for a period of two years from the date of the breach/violation of the aforesaid conditions.

4.12.3 The Offerers are also required to abstain from printing the words“ subject to jurisdiction of Delhi Courts only’ etc from on the invoices submitted, which may force the Corporation to entertain the payment only after the Offerer undertakes in writing his/ her agreeing to the conditions above in respect of the jurisdiction of the courts of Kerala. Any such statement made in any of the document presented to the EOI Inviting Authority will be inconsistent

with the terms and conditions of the EOI and the agreement thereof and the EOI Inviting Authority will not be party to the legal situations that might arise in pursuance of such statements.

4.13 Corrupt or Fraudulent Practices

4.13.1 It is required by all concerned namely the offerers / Successful offerers etc to observe the highest standard of ethics during the process, execution and operation of the contracts. In pursuance of this policy, the Corporation defines, for the purposes of this provision, the terms set forth below as follows:

4.13.2 "Corrupt practice" means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the Quality control process or in contract execution and operation; and

4.13.3 "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution or operation of a contract to the detriment of the EOI Inviting Authority, and includes collusive practice among offerers (prior to or after EOI submission) designed to establish testing fees at artificial non-competitive levels and to deprive the Corporation of the benefits of fair offer. Such other acts termed as fraudulent practices elsewhere in this document or any act to deceive the Corporation or any of its employees or any act adversely affecting or calculated to affect the normal/proper function or activities of the Corporation.

4.13.4 The EOI Inviting Authority will reject a proposal for award if it finds that the Offerer recommended for award has engaged in corrupt or fraudulent practices in fixing the testing fee and will declare a lab ineligible, either indefinitely or for a stated period of time, to be awarded a contract by the Corporation if it at any time determines that the lab has engaged in corrupt or fraudulent practices in fixing the testing fee, or in executing the contract.

4.13.5 No Offerer shall contact the Corporation or any of its officers or any officers of the Government on any matter relating to its offer so as to influence the members of various committees or the official(s) of EOI Inviting Authority. Any such act shall also constitute a fraudulent/ corrupt practice and would result in rejection of the EOI offer.

4.13.6 The Offerer shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Corporation in any trade or business or transactions nor shall the Offerer give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Custom" or otherwise, nor shall the Offerer permit any

person or persons whom so ever to interfere in the management or performance hereof under the power of attorney or otherwise without the prior consent in writing of the EOI Inviting Authority. Any such effort by the Offerer to influence the Corporation or its officers may result in rejection of the EOI offer. The terms 'Officers, subordinates or servant' shall include their family members or other associates also.

4.13.7 If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Kerala Medical Services Corporation Limited, the analytical Laboratory will be blacklisted for a period of five years. The Offerer shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for penal action against them.

4.14 Force Majeure

4.14.1 For purposes of this clause, Force Majeure means an event beyond the control of the successful Offerer and not involving the Empanelled laboratory's fault or negligence and which is not foreseeable and not brought about at the instance of, the party claiming to be affected by such event and which has caused the non – performance or delay in performance. Such events may include, but are not restricted to, acts of the Corporation either in its sovereign or contractual capacity, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quarantine restrictions, strikes excluding by its employees, lockouts excluding by the management, and freight embargoes. Scarcity of reagents, reference materials and power cut are not considered as force majeure.

4.14.2 If a Force Majeure situation arises, the Empanelled laboratory shall promptly notify the Corporation in writing of such conditions and the cause thereof within ten days of occurrence of such event. The time for completing the reporting may be extended by the Corporation at its discretion for such period as may be considered reasonable.

4.14.3 In case due to a Force Majeure event if the Corporation is unable to fulfill its contractual commitment and responsibility, the it will notify the Empanelled laboratory accordingly and subsequent actions taken on similar lines described in above sub-paragraphs.

4.15 Procedure for Blacklisting

4.15.1 For blacklisting a laboratory for defaulted reporting, a registered notice shall be issued to the laboratory calling for explanation within 15 days from the date of receipt of notice. On receipt of the explanation from the Laboratory, the EOI inviting Authority, may take appropriate action on merits of the case

and impose blacklisting of the particular laboratory by passing appropriate orders.

4.16 Provisions for Appeal

4.16.1 A laboratory which has been blacklisted by the Corporation may, within 15 days from the date of receipt of such order, appeal to the State Government. The State Government after such enquiry into the matter, as is considered necessary, and after giving the said supplier an opportunity for representing his views, may pass such order in relation thereto as it thinks fit.

4.17 Termination of Contract

4.17.1 Termination for default:- The Corporation without prejudice to any other contractual rights and remedies available to it (the EOI Inviting Authority), may, by written notice of default sent to the successful offerer (Empanelled laboratory), terminate the contract in whole or in part, if the successful offerer fails to perform any other contractual obligation(s) within the time period specified in the contract.

4.17.2 Unless otherwise instructed by the EOI Inviting Authority, the successful Offerer (Empanelled laboratory) shall continue to perform the contract to the extent not terminated.

4.17.3 Termination for insolvency: If the successful offerer becomes bankrupt or otherwise insolvent, the Corporation reserves the right to terminate the contract at any time, by serving written notice to the successful Offerer without any compensation, whatsoever, to the successful Offerer (Empanelled laboratory), subject to further condition that such termination will not prejudice or affect the rights and remedies which have accrued and / or will accrue thereafter to the EOI Inviting Authority.

4.17.4 Termination for convenience: - The Corporation reserves the right to terminate the contract, in whole or in part for its (EOI Inviting Authority's) convenience, by serving written notice on the successful Offerer (Empanelled laboratory) at any time during the currency of the contract. The notice shall specify that the termination is for the convenience of the EOI Inviting Authority. The notice shall also indicate interalia, the extent to which the successful offerers performance under the contract is terminated, and the date with effect from which such termination will become effective.

4.17.5. Termination due to change of ownership, constitution, suspension/ cancellation of statutory approval/ certification, accreditation etc.

4.17.6. Where there is a change of ownership (in the case of sole proprietorship unit) of the Empanelled laboratory under contract, the contract will stand

automatically terminated. The owner of the Empanelled laboratory shall inform the change of ownership to the EOI Inviting Authority as soon as the change takes place. The new owner will be eligible for a fresh contract for the remaining period of the earlier contract with the former owner under the same terms and conditions on deposit of the performance security amount. Inspection of the unit will be the discretion of the EOI Inviting Authority.

4.17.7. Where there is a change of constitution of the firm running the Empanelled Laboratory, the contract will stand terminated from the date of change of constitution if the person(s) responsible for the firm for the contract and its day to day operations change. In such an event the new firm will be eligible for further fresh contract for the remaining period of the earlier contract with the firm under the same terms and conditions. The performance security deposited earlier may be adjusted for the fresh contract on mutual agreement.

4.17.8. Where there is temporary or permanent suspension/ cancellation/ withdrawal/ revoking of the statutory approval/ certification/ accreditation on the basis of which the laboratory was empanelled and contract was awarded, the contract will stand terminated from the date of such action coming into force. Such termination may, however, be withdrawn if the action is cancelled or stayed by any competent forum. It will be onus of the Empanelled laboratory to report any such action taken against it.

(Sd/-)

Managing Director, KMSCL
&
(EOI Inviting Authority)

ANNEXURE-I

CHECK LIST

Name of the Laboratory : _____

Address : _____

Sl. No	Documents to be submitted	Page No
1.	Checklist (Annexure –I) for the list of documents enclosed with their page Nos. The documents should be serially numbered and arranged as per Annexure–I.	
2.	EOI Document Cost in the form of DD shall be kept in an envelope. DD No & date: Bank & branch: Amount in Rs:	
3.	Earnest Money Deposit the form of DD shall be kept in an envelope, **IF NOT EXEMPTED**, DD No & date: Bank & branch: Amount in Rs: **IF EXEMPTED** as per clause 4.2.4 valid documentary evidence to prove the claim.	
4.	Copy of notarized Documentary evidence for the constitution of the company /concern such as Memorandum and Articles of Association, along with notary attested copies of Form 32 whenever there is a change of Directors, Latest Partnership deed (Notary attested copy), Bye law in the case of society, trust etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor/ other responsible persons/ office bearers. The list of present MD & Directors of the firm shall	

Sl. No	Documents to be submitted	Page No
	also be furnished separately.	
5.	Annual turnover statement certified by the auditors for last three years i.e., 2012-13, 2013-2014 & 2014-15 as in (Annexure-V)	
6.	Notary Attested Photocopy of approval for testing of Drugs and the list of drugs approved for testing in the laboratory issued by the Drugs Control Authority and valid renewal with list of approved products for testing.	
7.	Notary Attested Photocopy of valid GLP Certificate issued by the Drugs Control Authority and valid renewal.	
8.	Notary Attested Photocopy of NABL accreditation certificate and its valid renewal.	
9.	Service Tax Clearance Certificate issued by the concerned authority and attested copy of certificate of registration for service tax.	
10.	Notary attested copies of audited Balance Sheet and Profit and Loss account for the last three years i.e. 2012-13, 2013-2014 & 2014-15.	
11.	The list of qualified personnel employed in the laboratory (Employees name, Qualification and experience)	
12.	The list of sophisticated analytical equipments & apparatus available in the laboratory. [Annexure III]	
13.	Duly filled performance statement in Annexure IV.	
14.	Declaration in the Proforma given in Annexure-VI duly signed and notarized	
15	Details of Analytical Laboratory in Annexure–II.	
16.	Consent letter of the offerer as in Annexure VII.	
17	EOI document signed by the offerer in all pages with office seal	
18	Notary attested copy of PAN.	

ANNEXURE – II

DETAILS OF ANALYTICAL LABORATORY

Sl.No.	Particulars	Details (To be filled in by the EOI Responder)
1.	Name of the Organization	
2.	Address(Regd. Office): Telephone: Fax: E-mail: Website:	
3.	Address(Laboratory Premises)***** Telephone: Fax: E-mail: Website: (***** If testing of the items are performed in more than one premises, details of all such units shall be furnished.)	
4.	Name of the Contact Person: Designation Telephone: Mobile: E-mail ID:	
5.	Type of the Organization (Public Sector/Limited/ Private Limited/Partnership/ Proprietary/Any Other):	
6.	Date of inception of the firm	
7.	Chief Officer of the Organization: Designation: E-mail ID: Telephone:	

Sl.No.	Particulars	Details (To be filled in by the EOI Responder)
8.	Registration No. & Date of Incorporation of Company:	
9.	License No. issued by the Drugs Control Dept. of the state for conducting the Analysis. Date of issue and current validity of the license period shall also be specified.	
10.	PAN no:	
11.	List of minimum 3 Clients as per clause No.3.2.5 (Provide number of samples, type, contact details like Address, Contact Person, e-mail ID, Telephone)	
12.	Total No. of Employees: 1. Technical Staff 2. Non-Technical Staff (Details of qualified personnels for testing of drugs/supplies)	
13.	Authorized Person/Persons responsible for signing the test report: 1. No: of Person/Persons 2. His/Her Name & Designation	
14.	Whether the License/Approval/ accreditation of the laboratory was cancelled / suspended by the authority in the past, if yes give details.	
15.	Whether any prosecution action is in progress or pending against the laboratory or any of	

Sl.No.	Particulars	Details (To be filled in by the EOI Responder)
	its. Furnish details of past conviction(s), if any.	

Date: Seal: Authorized Signatory:

ANNEXURE- III

LIST OF SOPHISTICATED ANALYTICAL EQUIPMENTS & APPARATUS AVAILABLE IN THE LABORATORY

Name of the Laboratory : _____

Address : _____

Name of the Equipment/ Instruments/Apparatus	Name & Description	Date of Installation	Working Conditions
FACILITIES IN THE MICROBIOLOGICAL SECTION			
List of Equipments / Apparatus Available with Date of Installation (eg. Incubators, Autoclave etc.)			

Date: Seal: Authorized Signatory:

ANNEXURE- IV

PROFORMA FOR PERFORMANCE STATEMENT

(for a period of last 3 years)

Name of the Laboratory : _____

Address : _____

_____

Types of Samples Analyzed		No. of Samples Analyzed during		
		2012-13	2013-14	2014-15
1	Tablets / Capsules			
2	Injectable			
3	Liquid Orals			
4	Ointments / Creams / Gels			
5	Surgicals (Specify item names)			
6	Sutures (Specify types)			
7	Other Categories (Specify)			
8	Other Categories (Specify)			

Signature :
Date :
Name of the Lab :
Office Seal :

ANNEXURE- V

ANNUAL TURN OVER STATEMENT

I hereby certify that M/s _____ (Name & address _____) who is participating in the **EOI No. KMSCL/QC/EOI/2016/01 DATED 05.10.2016** of KMSCL is having the following annual turnover and the statement is true and correct.

Sl. No.	Year	Turnover (Rs.)
1.	**2012 – 2013**	
2.	**2013 - 2014**	
3.	**2014 - 2015**	
Total (Rs.)		
Average turnover per annum (Rs.)		

Date:

Signature of Auditor/
Chartered Accountant

(Name in Capital) :
Name of firm :

Reg. No. :

Seal:

ANNEXURE-VI

DECLARATION

I / We …… (Name of the laboratory) having our office at ……
……
Lababoratory at …… ……. ……. ……. do declare that I / We have carefully read all the conditions of **EOI No. KMSCL/QC/EOI/2016/01 DATED 05.10.2016** of Kerala Medical Services Corporation Ltd., Thiruvananthapuram, for the EOI floated for empanelment of analytical testing laboratories for the analysis of drugs and supplies, for a period of two years from the date of acceptance and abide by all conditions set forth therein. I/We do accept(s) all the terms and conditions of the above EOI document including amendments of the tender, if any, published by the Corporation.

`

Signature :
Date :
Name of the Lab :

Office Seal :

ATTESTED BY NOTARY PUBLIC

ANNEXURE-VII

CONSENT LETTER OF THE OFFERER

From

Name of the Laboratory……..

Address ……..

To

The EOI Inviting Authority

Sir,

Sub: Consent for performing complete analysis of drugs/supplies.

Ref : KMSCL/QC/EOI/2016/01 dated 05.10.2016.

With reference to the EOI for the empanelment of drugs testing laboratories, we here by submit our consent to perform the complete analysis of the following items of drugs/supplies in Appendix I-A & Appendix I-B of the EOI document at the rates offered in column 6 of the following tables and as per the conditions stipulated in the EOI documents referred above.

Table.I **LIST OF ITEMS OFFERED IN APPENDIX I-A**

Sl.No.	Category	Drug Code	Drug Name	Strength	Unit	Agreed rate (Rs.)
(1)		(2)	(3)	(4)	(5)	(6)

Table.II **LIST OF ITEMS OFFERED IN APPENDIX I-B**

Sl.No.	Category	Drug Code	Drug Name	Strength	Unit	Offered rate (Rs.)
(1)		(2)	(3)	(4)	(5)	(6)

Date: Seal: Authorized Signatory:

ANNEXURE-VIII

FORMAT OF BANK GUARANTEE FOR SECURITY DEPOSIT

To
The Kerala Medical Services Corporation Limited
(Address)

WHEREAS _____ (Name and address of the Laboratory) has undertaken, in pursuance of contract no_____ dated _____ (herein after called "the contract") to conduct quality control analysis for Kerala Medical Services Corporation Limited, (address).

AND WHEREAS it has been stipulated by you in the said contract that the Laboratory shall furnish you with a bank guarantee by a scheduled commercial bank recognised by you for the sum specified therein as security for compliance with its obligations in accordance with the contract;

AND WHEREAS we have agreed to give the Laboratory such a bank guarantee;

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the Laboratory, up to a total amount of _____ (Amount of the guarantee in words and figures), and we undertake to pay you, upon your first written demand declaring the Laboratory to be in default under the contract and without cavil or argument, any sum or sums within the limits of (amount of guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the Laboratory before presenting us with the demand.

We undertake to pay you any money so demanded notwithstanding any dispute or disputes raised by the Laboratory (s) in any suit or proceeding pending before any Court or Tribunal relating thereto our liability under these presents being absolute and unequivocal.

We agree that no change or addition to or other modification of the terms of the contract to be performed there under or of any of the contract documents

which may be made between you and the Laboratory shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

No action, event, or condition that by any applicable law should operate to discharge us from liability, hereunder shall have any effect and we hereby waive any right we may have to apply such law, so that in all respects our liability hereunder shall be irrevocable and except as stated herein, unconditional in all respects.

This guarantee will not be discharged due to the change in the constitution of the Bank or the Laboratory (s).

We, _____ (indicate the name of bank) lastly undertake not to revoke this guarantee during its currency except with the previous consent, in writing, of The Kerala Medical Services Corporation Limited.

This Guarantee will remain in force up to---------- (Date). Unless a claim or a demand in writing is made against the bank in terms of this guarantee on or before the expiry of ---------- (Date) all your rights in the said guarantee shall be forfeited and we shall be relieved and discharged from all the liability there under irrespective of whether the original guarantee is received by us or not.

(Signature with date of the authorised officer of the Bank)
……
Name and designation of the officer
……
……
Seal, name & address of the Bank and address of the Branch

ANNEXURE-IX

AGREEMENT

THIS AGREEMENT made on this ……. day of ……., 20… between …….. Kerala Medical Services Corporation Ltd represented by its Managing Director (& Expression of Interest (EOI) Inviting Authority) having its registered office at Thiruvananthapuram (hereinafter mentioned as "The KMSCL" or the Corporation) of one part and M/s. ……
……
… (Name and Address of the laboratory)(hereinafter called as "The Empanelled laboratory" or the "Laboratory" in short) represented by ……. (Name of the authorized signatory and Designation), aged ……. Years, residing at ……. (Full residential address of the signatory) of the other part.

WHEREAS the KMSCL had invited Expression of Interest (EOI) from eligible Analytical Laboratories for test and analysis of Drugs and other consumables procured by it for supply to the healthcare institutions under the Health & Family Welfare Department of Kerala as per the EOI document number .....dated ..... and had prescribed eligible criteria and various terms and conditions for participation and presentation of the EOI, and

WHEREAS The Empanelled Laboratory above has offered to the KMSCL to undertake analytical work of the list of items mentioned in the Annexure attached hereto, in accordance with the terms and conditions specified in the above said EOI document, at the rates noted therein and had given an undertaking in writing to those effects and in the manner and under the terms and conditions hereinafter mentioned, and

WHERAS the EOI Inviting Authority (KMSCL) has accepted the offer, and

The Empanelled Laboratory has deposited with the KMSCL a sum of Rs.50,000/-(Rupees Fifty Thousand) as Security Deposit for the due and faithful performance of this Agreement and liable to be forfeited as

liquidated damages in the event of the Laboratory failing duly and faithfully to perform its obligations set forth hereinafter.

In this agreement words and expressions shall have the same meanings as are respectively assigned to them in the EOI document referred to.

Now therefore these presents witness that for carrying out the said Agreement in this behalf into execution, The Empanelled Laboratory and the KMSCL do hereby mutually covenant ,declare, contract and agree each of them with the other of them in the manner following, that is to say,

1. The term "Agreement", wherever used in this connection, shall mean the terms and conditions stipulated hereinafter for the analysis of Drugs, surgical and other items for the year 2017 -19.

2. (a) The agreement is for undertaking analysis of Drugs, Surgical items & Sutures items by the Empanelled Laboratory to the KMSCL of the samples specified in the …… (will specify later) attached hereto at the rates noted against each therein on the terms and conditions set forth in this Agreement and strictly within the time frame stipulated for the respective items in clause 3.1 of the EOI document.

(b) This agreement shall be deemed to have come into force with effect from ---------- (Date of execution of agreement) and it shall remain in force for a period of two years with effect from that date and may however be extended for a further period, on mutually agreed terms signed by both parties.

(c) The time frame specified in clause 3.1 of the EOI document for the respective item shall be strictly adhered to by the Laboratory. Tests and Analysis of drugs and other items will be performed in accordance with the statutory standards such as IP, BP, USP, BIS etc and in the case of items for which no official standards, by applying such recognized or prescribed or authentic parameters of standard quality and the test reports shall reach the KMSCL within the maximum time limit specified in the EOI document reckoned from the date on which the item to be tested is delivered to the Empanelled Laboratory, failing which the measures of penalty and others specified will be applicable.

(d) The test reports are to be submitted to the KMSCL by email within the time period specified in clause 3.1 of the EOI document at the email address

of the KMSCL (kmsclqcresults@gmail.com) to be followed by three sets of hardcopies duly authenticated.

(e) In the event of any failure/default/deviations from the EOI agreement on the part of the Empanelled Laboratory with or without any quantifiable loss to the KMSCL, the amount of the performance security is liable to be forfeited. If the Empanelled Laboratory withdraws from the contract during the period of contract, the security deposit shall be liable to be forfeited, the contract terminated and the Empanelled Laboratory shall be liable to be blacklisted for a period of three years from the date of such order making them ineligible to participate in any of the offers/Tender of the Corporation.

3. In respect of the analysis of items in the Schedule, the Laboratory shall allow inspection of the laboratory at any time during the continuance of the contract period by a team of Experts/Officials whom the KMSCL may depute for the purpose. The laboratory shall extend all facilities to the team to enable them to inspect sample storage, reagents, instruments, all relevant records, analysis etc, in the Empanelled Laboratory and also to take photographs of such facilities, which shall not be used by the Corporation other than pursuance of actions under the terms and conditions of this contract and also of the EOI document.

4. All expenses, damages and other moneys payable to the KMSCL by the Empanelled Laboratory under any provisions of this Agreement may be recovered from the amounts due or subsequently becoming due from the KMSCL to the Laboratory under this or any other Agreement. In case such amount are insufficient to fully cover such expenses, damages or other moneys payable. It shall be lawful for the KMSCL to recover the balance amount from the security deposit of the laboratory and all other money held by KMSCL and in case such security deposit is insufficient then it shall be also be lawful for the KMSCL to recover the residue of the expenses, damages and moneys, if necessary by means of legal proceeding against the Empanelled Laboratory.

5. The amount of security deposit remitted by the Laboratory to the KMSCL by way of Demand Draft by favoring the Managing Director, KMSCL, Thiruvananthapuram will be returned on successful fulfillment of the terms and conditions of this agreement without any interest.

6. (a) No advance payment towards any analysis will be made to the Empanelled Laboratory.

(b) All bills/invoices should be raised in triplicate in the name of the managing director Kerala Medical Services Corporation Limited. All payments will be made only by way of electronic fund transfer in favour of the Empanelled Laboratory for which bank details shall be furnished to the Corporation at the time of entering into agreement.

(c) The Empanelled Laboratory shall furnish the test reports within:

I. 15 days of receipt of the samples in case of Tablets, Capsules, Pessaries, Ointments, Powders and Liquid Oral Preparations, and all Non- Sterile preparations

II. 30 days of receipt of the samples in the case of all sterile preparations.

7. The Empanelled Laboratory shall not at anytime assign, sub-let or make over the present Contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

8. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

(a) All the documents submitted by the Empanelled Laboratory as a part of the EOI offer,

(b) The Schedule of Requirements;

(c) The Specifications and other quality parameters;

(d) The clarifications and amendments issued / received as part of the EOI Document

(e) All correspondence as part of tender during or after the date of agreement accepted by Tender Inviting Authority

9. The terms and conditions specified in the EOI document published by the EOI Inviting Authority in acceptance of which the Empanelled Laboratory had presented the EOI offer will apply in matters not specifically in this agreement.

10. The Empanelled Laboratory and the Corporation mutually agree that any and all disputes arising out of this Agreement will be subject only to the jurisdiction of courts of law / tribunals situated in Thiruvananthapuram city or normally having territorial jurisdiction over Thiruvananthapuram city only or the High Court of Kerala as applicable and the provisions of clause 4.12 of the EOI document are agreed to in full.

In witness whereof the parties hereto have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

said ……..... (For the EOI Inviting Authority- KMSCL)

in the presence of,

1. …….. (Signature, name and Address)

2. …….. (Signature, name and Address)

Signed, Sealed and Delivered by the

said ……..... (For the Empanelled Laboratory)
(Signature, Name and Address with Office Seal)

in the presence of,

1. …….. (Signature, name and Address)

2. …….. (Signature, name and Address)

CERTIFICATE No:
NABL CERTIFICATE NO:
VALID UPTO:

	:
	:
	:
	:
Analysis Started	:
Analysis Completed	:
Details of Raw Material/Final Product	:
a) Sample Quantity	:
b) Drug Code/Product Code	:
c) Strength	:
d)	:
	:
	:

Results of Test/Analysis with Protocol

SL. NO	TEST	RESULTS	SPECIFICATION	TEST METHOD
1.	DESCRIPTION	WHITE CIRCULAR UNCOATED TABLETS HAVING A BISECTING LINE ON ONE SIDE		
2.	IDENTIFICATION	COMPLIES	Complies with I.P	IP 2014
3.	RELATED SUBSTANCES	COMPLIES	NMT 0.25%	IP 2014
4.	DISSOLUTION	94.65%	D-NLT 80%	IP 2014
5.	UNIFORMITY OF WEIGHT	COMPLIES	NMT TWO OF THE INDIVIDUAL WEIGHT DEVIATES 5%FROM AVERAGE WEIGHT	IP 2014
6.	ASSAY AS PARACETAMOL	483.84MG/TAB (96.77%)	475 MG/TAB TO 525 MG/TAB (95% TO 105%)	IP 2014

LABEL CLAIM: 500MG/TAB
COMPLIES TO IP 2014

Laboratory Seal

FOR AND ON BEHALF OF
Person In-charge of Testing

Name and Designation

Appendix- IA

List of items with pre-fixed laboratory testing rates

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
1	ACD	D24056C	ACTINOMYCIN D INJ	0.5mg/3ml	Vial	825
2	ACD	D24058C	ANASTRAZOLE TAB IP	1mg	1 No	990
3	ACD	D24061C	BICALUTAMIDE TAB IP	50mg	1 No	913
4	ACD	D24062C	BLEOMYCIN INJ IP	15mg	Vial	968
5	ACD	D24063C	BORTEZOMIB INJ	2mg	Vial	668
6	ACD	D24066C	CAPECITABINE TAB IP	500mg	1 No	693
7	ACD	D24067C	CARBOPLATIN INJ	150mg	Vial	1155
8	ACD	D24068C	CARBOPLATIN INJ	450mg	Vial	1155
9	ACD	D24071C	CISPLATIN INJ	10mg	Vial	1155
10	ACD	D24072C	CISPLATIN INJ IP	50mg	Vial	1155
11	ACD	D24076C	CYCLOPHOSPHAMIDE TAB IP	50mg	1 No	424
12	ACD	D24077C	CYTARABINE INJ IP	100mg	Vial	1045
13	ACD	D24161C	DEXAMETHASONE TAB	8mg	1 No	1670
14	ACD	D24087C	DOXORUBICIN INJ (LYOPHILISED)	10mg	Vial	1210
15	ACD	D24088C	DOXORUBICIN INJ (LYOPHILISED)	50mg	Vial	1210
16	ACD	D24092C	EPIRUBICIN INJ	10mg	Vial	1100
17	ACD	D24093C	EPIRUBICIN INJ	50mg	Vial	1100
18	ACD	D24054C	FLUROURACIL INJ IP	250mg	Amp	1073
19	ACD	D24103C	GEFITINIB TAB IP	250mg	1 No	715
20	ACD	D24105C	GEMCITABINE INJ	1gm	Vial	1320
21	ACD	D24104C	GEMCITABINE INJ IP	200mg	Vial	1320
22	ACD	D24109C	IBANDRONATE TAB	50mg	1 No	770
23	ACD	D24110C	IFOSFAMIDE WITH MESNA INJ	1gm	Vial	1183
24	ACD	D24111C	IFOSFAMIDE WITH MESNA INJ	2gm	Vial	1183
25	ACD	D24113C	IMATINIB CAP/ TAB IP	400mg	1 No	589
26	ACD	D24112C	IMATINIB CAP/ TAB IP	100mg	1 No	589
27	ACD	D24116C	IRINOTECAN INJ	100mg	Vial	1073

28	ACD	D24115C	IRINOTECAN INJ	40mg	Vial	1073
29	ACD	D24119C	LENALIDOMIDE CAP	10mg	1 No	660
30	ACD	D24120C	LETREZOLE TAB	2.5mg	1 No	825
31	ACD	D24121C	LEUPROLIDE ACETATE INJ	3.75mg	Vial	1100
32	ACD	D24123C	LOMUSTINE CAP IP	40mg	1 No	770
33	ACD	D24125C	MESNA INJ	200mg	Amp	963
34	ACD	D24127C	METHOTREXATE INJ IP	50mg	Vial	1089
35	ACD	D24126C	METHOTREXATE INJ IP (INTRATHECAL, PESERVATIVE FREE)	15mg	Vial/PFS	1089
36	ACD	D24128C	METHOTREXATE TAB IP	2.5mg	1 No	495
37	ACD	D24129C	MITOMYCIN INJ	2mg	Vial	1210
38	ACD	D24130C	MITOMYCIN INJ	10mg	Vial	1210
39	ACD	D24131C	MITOXANDRONE INJ	20mg	Vial	1320
40	ACD	D24133C	OXALIPLATIN INJ	50mg	Vial	1182
41	ACD	D24134C	OXALIPLATIN INJ	100mg	Vial	1182
42	ACD	D24136C	PACLITAXEL INJ IP	30mg	Vial	1100
43	ACD	D24137C	PACLITAXEL INJ IP WITH CODON SET	100mg	Vial	1100
44	ACD	D24138C	PACLITAXEL INJ IP WITH CODON SET	260mg	Vial	1100
45	ACD	D24141C	PEMETREXED INJ	100mg	Vial	1073
46	ACD	D24142C	PEMETREXED INJ	500mg	Vial	1073
47	ACD	D24143C	PROCARBAZINE HCL CAP	50mg	1 No	407
48	ACD	D24147C	SORAFENIB TOSYLATE TAB	200mg	1 No	584
49	ACD	D24150C	TAMOXIFEN TAB IP	20mg	1 No	715
50	ACD	D24151C	TEMOZOLOMIDE CAP IP	20mg	1 No	583
51	ACD	D24152C	TEMOZOLOMIDE CAP IP	100mg	1 No	583
52	ACD	D24154C	THALIDOMIDE CAP	100mg	1 No	770
53	ACD	D24160C	ZOLEDRONIC ACID INJ IP	4mg	Vial	963
54	CAT-I	D01019	ACECLOFENAC TAB IP	100mg	1 No	341
55	CAT-I	D19006	ACETAZOLAMIDE TAB IP	250mg	1 No	535
56	CAT-I	D13036	ACETYL SALICYLIC ACID TAB IP(GASTRO-RESISTANT)	150mg	1 No	418

57	CAT-I	D13024	ACETYLSALICYLIC ACID TAB IP(GASTRO-RESISTANT)	75mg	1 No	418
58	CAT-I	D06002/12	ACTIVATED CHARCOAL IP	10gm	Packet	220
59	CAT-I	D09003	ACYCLOVIR CREAM IP	5% w/w	5gm Tube	751
60	CAT-I	D15014	ACYCLOVIR EYE OINTMENT IP	3%	5gm Tube	619
61	CAT-I	D09001	ACYCLOVIR INJ IP	250 mg	Vial	751
62	CAT-I	D09002/12	ACYCLOVIR TAB IP	400 mg	1 No	751
63	CAT-I	D13062	ADENOSINE INJ IP	3mg/ml	2ml amp	2120
64	CAT-I	D05005	ADRENALINE BITARTRATE INJ IP	1mg/ml	1 ml Amp	1593
65	CAT-I	D08015	ALBENDAZOLE ORAL SUSPENSION IP	200 mg/5ml	10 ml Bottle	418
66	CAT-I	D08001	ALBENDAZOLE TAB IP	400 mg	1 No	460
67	CAT-I	D01013	ALLOPURINOL TAB IP	100 MG	1 No	501
68	CAT-I	D17007/12	ALPRAZOLAM TAB IP	0.25mg	1 No	584
69	CAT-I	D02091	AMIKACIN SULPHATE INJ IP	250mg/2ml	2ml Vial	751
70	CAT-I	D03003	AMINOPHYLLINE INJ IP	25mg/ml	10ml Amp	642
71	CAT-I	D13040	AMIODARONE INJ IP	50mg/ml	3 ml	759
72	CAT-I	D13041	AMIODARONE TAB IP	100mg	1 No	668
73	CAT-I	D17005	AMITRIPTYLINE TAB IP	25mg	1 No	668
74	CAT-I	D13031/12	AMLODIPINE TAB IP(FILM COATED)	5 mg	1 No	1086
75	CAT-I	D02036/12	AMOXICILLIN AND POTASSIUM CLAVULANATE TAB IP	500mg 125mg	1 No	880
76	CAT-I	D02049	AMOXYCILLIN AND POTASSIUM CLAVULANATE INJ IP	1.2 g/10 ml	Vial	880
77	CAT-I	D02047	AMOXYCILLIN AND POTASSIUM CLAVULANATE ORAL SUSPENSION IP	(200mg 28.5mg) or (400mg + 57mg)	30 ml bottle	935
78	CAT-I	D02004	AMOXYCILLIN CAP IP	250 mg	1 No	501
79	CAT-I	D02005	AMOXYCILLIN CAP IP	500 mg	1 No	501
80	CAT-I	D02032	AMOXYCILLIN ORAL SUSPENSION IP	(125 mg/5 ml) or (250mg/5 ml)	60 ml Bottle	886
81	CAT-I	D02007	AMPICILLIN CAP IP	250 mg	1 No	501
82	CAT-I	D02041	AMPICILLIN CAP IP	500mg	1 No	429
83	CAT-I	D02008	AMPICILLIN INJ IP	500 mg	Vial	1712

84	CAT-I	D08031	ARTESUNATE +(SULPHADOXINE + PYREMETHAMINE)	Each Combi Blister Pack contains; [3 tablets of Artesunate (each 200mg) and 2 tablets of Sulphadoxine + Pyremethamine (each 750mg + 37.5mg)] OR [3 tablets of Artesunate (each 200mg) and 3 tablets of Sulphadoxine + Pyremethamine (each 500mg + 25mg)]	1 Blister Pack	880
85	CAT-I	D08019	ARTESUNATE INJ	60mg	Vial	1045
86	CAT-I	D13008	ATENOLOL TAB IP	50 mg	1 No	1002
87	CAT-I	D13013	ATORVASTATIN TAB IP	10 mg	1 No	1252
88	CAT-I	D15016	ATROPINE EYE DROPS	1%	5 ml bottle	627
89	CAT-I	D15017	ATROPINE EYE OINTMENT IP	1%w/w	5gm	482
90	CAT-I	D04007	ATROPINE SULPHATE INJ IP	0.6mg/ml	1 ml Amp	1086
91	CAT-I	D06017	ATROPINE SULPHATE INJ IP	1mg/ml	100ml	1002
92	CAT-I	D02052	AZITHROMYCIN INJ	500mg	10 ml Vial	990
93	CAT-I	D02053	AZITHROMYCIN ORAL SUSPENSION IP	(100mg/5 ml) or (200mg/ 5ml)	30 ml bottle	770
94	CAT-I	D02031	AZITHROMYCIN TAB IP	500 mg	1 No	886
95	CAT-I	D01026	BACLOFEN TAB	5mg	1 No	770
96	CAT-I	D15018	BALANCED SALT SOLUTION FOR OPHTHALMIC USE(GLASS BOTTLE/OT PACK)	500 ml	Bottle	550
97	CAT-I	D26001	BENEDICTS REAGENT SOLUTION	500 ml	Bottle	418
98	CAT-I	D14026/12	BENZYL BENZOATE APPLICATION IP	25% w/v,	100 ml bottle	330
99	CAT-I	D02009	BENZYL PENCILLIN INJ IP	10 lakhs units	Vial	1845
100	CAT-I	D05017	BETAHISTINE TAB IP	8mg	1 No	880
101	CAT-I	D15007	BETAMETHASONE EYE DROPS IP	0.1%w/v	5ml/Bot	668
102	CAT-I	D05004	BETAMETHASONE SODIUM INJ IP	4mg/ml	1ml Amp	1002

103	CAT-I	D14009/12	BETAMETHASONE VALERATE CREAM IP	0.1%w/w	5 gm Tube	668
104	CAT-I	D20012	BISACODYL TAB IP	5mg	1 No	668
105	CAT-I	D15021	BRIMONIDINE EYE DROPS	0.20%	5 ml	751
106	CAT-I	D11005	BROMOCRIPTINE TAB	1.25mg	1 No	668
107	CAT-I	D04017	BUPIVACAINE IN DEXTROSE INJ USP	0.50%	4 ml Amp	1139
108	CAT-I	D14030/12	CALAMINE LOTION I.P	50 ml	bottle	330
109	CAT-I	D22012/12	CALCIUM CARBONATE WITH VITAMIN D3 TAB	625mg + 200IU	1 No	715
110	CAT-I	D22003	CALCIUM GLUCONATE INJ IP	10%w/v	10ml	751
111	CAT-I	D07024	CARBAMAZEPINE SYRUP	100mg/5 ml	30 ml bottle	605
112	CAT-I	D07005	CARBAMAZEPINE TAB IP	200 mg	1 No	584
113	CAT-I	D11002	CARBIDOPA + LEVODOPA TAB IP	10mg+100mg	1 No	1419
114	CAT-I	D11007	CARBIDOPA + LEVODOPA TAB IP	25mg+ 100mg	1 No	1419
115	CAT-I	D13045	CARVEDILOL TAB IP	6.25mg	1 No	798
116	CAT-I	D02035	CEFADROXIL TAB IP	500mg	1 No	979
117	CAT-I	D02094	CEFAZOLIN SODIUM INJ IP	1gm	Vial	2045
118	CAT-I	D02055	CEFIXIME TAB IP	200mg	1 No	990
119	CAT-I	D02056	CEFOPERAZONE + SULBACTAM INJ	1gm+ 0.5gm	Vial	638
120	CAT-I	D02010	CEFOTAXIME SODIUM INJ IP	250mg	Vial	1670
121	CAT-I	D02026	CEFOTAXIME SODIUM INJ IP	1gm	Vial	1670
122	CAT-I	D02057	CEFPODOXIME PROXETIL TAB IP	200mg	1 No	990
123	CAT-I	D02034	CEFTRIAXONE INJ IP	1gm	Vial	770
124	CAT-I	D02020	CEFUROXIME INJ IP	750 mg	Vial	1670
125	CAT-I	D02022	CEPHALEXIN ORAL SUSPENSION (DRY) IP	125 mg/5ml	30 ml Bottle	668
126	CAT-I	D05018	CETIRIZINE SYRUP IP	5mg/ 5ml	30 ml Bottle	572
127	CAT-I	D05010	CETIRIZINE TAB IP	10 mg	1 No	793
128	CAT-I	D17009	CHLORDIAZEPOXIDE TAB IP	10 MG/ 25 MG	1 No	668
129	CAT-I	D14022	CHLORHEXIDINE MOUTH WASH IP	60 ml	bottle	330
130	CAT-I	D08009	CHLOROQUINE PHOSPHATE TAB IP	250 mg	1 No	668

131	CAT-I	D05008	CHLORPHENIRAMINE MALEATE INJ IP	10 mg/ml	1 ml Amp	668
132	CAT-I	D05019	CHLORPHENIRAMINE MALEATE TAB IP	4mg	1 No	877
133	CAT-I	D17003	CHLORPROMAZINE TAB IP	100MG/ 50MG	1 No	651
134	CAT-I	D17035	CINNARIZINE TAB IP	25 mg	1 No	495
135	CAT-I	D15024	CIPROFLOXACIN + DEXAMETHASONE EAR DROPS	0.3 %+ 0.1 %	10 ml	825
136	CAT-I	D02063	CIPROFLOXACIN + TINIDAZOLE TAB	500mg + 600mg	1 No	894
137	CAT-I	D15002	CIPROFLOXACIN EYE/EAR DROPS	0.3%w/v	5mlBottle	751
138	CAT-I	D02012	CIPROFLOXACIN INJ IP	2 mg/ml	100ml Bottle	1937
139	CAT-I	D02011	CIPROFLOXACIN TAB IP	500 mg	1 No	1086
140	CAT-I	D02065	CLARITHROMYCIN TAB IP	500mg	1 No	1770
141	CAT-I	D02090	CLINDAMYCIN + CLOTRIMAZOLE VAGINAL PESSARY	100mg+ 200 mg	1 No	743
142	CAT-I	D07009	CLOBAZAM TAB	5 mg	1 No	668
143	CAT-I	D14031	CLOBETASOLE PROPIONATE CREAM IP	0.05%	15gm Tube	660
144	CAT-I	D16009	CLOMIPHENE CITRATE TAB IP	50mg	1 No	935
145	CAT-I	D17061	CLOMIPRAMINE CAP IP	25mg	1 No	1200
146	CAT-I	D17038	CLONAZEPAM TAB IP	0.5 mg	1 No	682
147	CAT-I	D13046	CLONIDINE TAB IP	100mcg	1 No	715
148	CAT-I	D13023	CLOPIDOGREL TAB IP	75 MG	1 No	668
149	CAT-I	D08038	CLOTRIMAZOLE CREAM IP	(2% w/w) or (1% w/w)	10gm Tube	584
150	CAT-I	D08021	CLOTRIMAZOLE MOUTH PAINT	1%	15 ml	660
151	CAT-I	D08008	CLOTRIMAZOLE VAGINAL TAB IP	200 mg	1 No	584
152	CAT-I	D02006	CLOXACILLIN CAP IP	250 mg/ 500 mg	1 No	584
153	CAT-I	D02029	CLOXACILLIN INJ IP	500MG	IM/IV VIAL	1139
154	CAT-I	D02070	CLOXACILLIN SYRUP IP	125mg/5ml	60 ml bottle	584
155	CAT-I	D17014	CLOZAPINE TAB IP	25MG	1 No	751
156	CAT-I	D17015	CLOZAPINE TAB IP	100mg	1 No	751
157	CAT-I	D02002	CO-TRIMOXAZOLE ORAL SUSPENSION IP	40mg 200mg	50 ml Bottle	501
158	CAT-I	D02001	CO-TRIMOXAZOLE TAB IP	160mg+ 800mg	1 No	584

159	CAT-I	D03009/12	COUGH SYRUP	Each 5 ml contains: CPM-IP 2mg, Ammonium	50 ml Bottle	501
160	CAT-I	D15025	CYCLOPENTOLATE 1 % AND PHENYL EPHRINE 5 % OPHTHALMIC SOLUTION	1 % + 5 %	5 ml	660
161	CAT-I	D05021	DEFLAZACORT TAB	6mg	1 No	835
162	CAT-I	D05001	DEXAMETHASONE SODIUM INJ IP	4 mg/ml	2 ml Vial	668
163	CAT-I	D05003	DEXAMETHASONE TAB IP	0.5 mg	1 No	668
164	CAT-I	D04024	DEXMEDITOMEDINE INJ	200 mcg/2ml	2 ml amp	715
165	CAT-I	D18003	DEXTROSE INJ IP	5%	500ml Bot	1503
166	CAT-I	D18004	DEXTROSE INJ IP	10%	500ml Bot	1503
167	CAT-I	D18006	DEXTROSE INJ IP	25%	100ml bottle	1503
168	CAT-I	D07007	DIAZEPAM INJ IP	5 mg/ml	2ml Amp.	1135
169	CAT-I	D17001	DIAZEPAM TAB IP	5mg	1 No	893
170	CAT-I	D01028	DICLOFENAC SODIUM GEL	1% w/w	25gm Tube	550
171	CAT-I	D01005	DICLOFENAC SODIUM INJ IP	25 mg/ml	3 ml amp	876
172	CAT-I	D01004	DICLOFENAC SODIUM TAB IP(GASTRO-RESISTANT)	50 mg.	1 No	484
173	CAT-I	D20009	DICYCLOMINE HCL INJ IP	10mg/ml	2ml Amp	1002
174	CAT-I	D20008	DICYCLOMINE HCL TAB IP	10 mg	1 No	584
175	CAT-I	D08003	DIETHYL CARBAMAZINE TAB IP	100 mg	1 No	484
176	CAT-I	D13015	DIGOXIN INJ IP	0.5mg/2 ml	2 ml	1670
177	CAT-I	D13014	DIGOXIN TAB IP	0.25 mg	1 No	1253
178	CAT-I	D13004	DILTIAZEM TAB IP	30 mg	1 No	1002
179	CAT-I	D13017	DOBUTAMINE HCL INJ	50 mg/ml	5 ml Amp	1670
180	CAT-I	D20007/12	DOMPERIDONE TAB IP (FILM COATED)	10 mg	1 No	542
181	CAT-I	D17062	DONEPEZIL TAB IP	10mg	1 No	2250
182	CAT-I	D13016	DOPAMINE HCL INJ IP	40 mg/ml	5 ml	1086
183	CAT-I	D15027	DORZOLAMIDE + TIMOLOL EYE DROPS	2 % + 0.5 %	5 ml	660
184	CAT-I	D15028	DORZOLAMIDE EYE DROPS	2%	5 ml	660
185	CAT-I	D02014/12	DOXYCYCLINE TAB	100 mg	1 No	1002

186	CAT-I	D18007/12	ELECTROLYTE P(MULTI ELECTROLYTE IN D 5%) INJ	500ml	Bottle	1753
187	CAT-I	D13032/12	ENALAPRIL MALEATE TAB IP(FILM COATED)	5 mg	1 No	835
188	CAT-I	D17029	ESCITALOPRAM TAB IP	10 mg	1 No	605
189	CAT-I	D03009	EXPECTORANT MIXTURE CONCENTRATED	Each 5ml contains: Camphorated Opium Tincture IP 66- 1.62 ml, Tincture Ipecacuanha IP 66 – 0.875 ml, Tincture Urgenia IP 66 - 0.75 ml, Aromatic Spirit of Ammonia IP 66 - 0.875 ml, Chloroform IP 0.025 ml, Water QS, Alcohol Content 40- 45% v/v.	500 ml Bottle	501
190	CAT-I	D22006	FERROUS SULPHATE TAB IP	200 mg	1 No	418
191	CAT-I	D08014	FLUCONAZOLE TAB IP	150 MG	1 No	601
192	CAT-I	D05037	FLUNARIZINE TAB	10mg	1 No	825
193	CAT-I	D15029	FLUOROMETHOLONE EYE DROPS IP	0.10%	5 ml	584
194	CAT-I	D17036	FLUOXETINE CAP IP	20 mg	1 No	726
195	CAT-I	D17013	FLUPHENAZINE DECANOATE INJ IP	25MG	1ML Amp	1753
196	CAT-I	D15030	FLURBIPROFEN EYE DROPS IP	0.03%	5 ml	584
197	CAT-I	D12002	FOLIC ACID TAB IP	5 mg	1 No	877
198	CAT-I	D19002	FRUSEMIDE INJ IP	10mg/ml	2ml Amp	877
199	CAT-I	D19001	FRUSEMIDE TAB IP	40mg	1 No	459
200	CAT-I	D14032	FUSIDIC ACID CREAM IP	2%	10gm tube	330
201	CAT-I	D07016	GABAPENTIN TAB	100mg	1 No	605
202	CAT-I	D14010	GAMMA BENZENE HEXA CHLORIDE SOLUTION	1%w/v	100ml Bottle	418
203	CAT-I	D02013	GENTAMICIN INJ IP	80 mg/2ml	IM/IV VIAL	1586
204	CAT-I	D21001	GLIBENCLAMIDE TAB IP	5mg	1 No	668
205	CAT-I	D21028	GLIMEPIRIDE TAB IP	1 mg	1 No	880
206	CAT-I	D21032/12	GLIMEPIRIDE TAB IP	2mg	1 No	880
207	CAT-I	D14029/12	GLYCERINE IP	100gm	bottle	330

208	CAT-I	D13047	GLYCERYL TRINITRATE TAB	2.6mg	1 No	619
209	CAT-I	D04019	GLYCOPYRROLATE INJ	0.2mg/ml	1ml Amp	1139
210	CAT-I	D17012	HALOPERIDOL INJ IP	5mg/ml	1ml Amp	1753
211	CAT-I	D17010	HALOPERIDOL TAB IP	5 mg	1 No	751
212	CAT-I	D17052	HALOPERIDOL TAB IP	1.5mg	1 No	1420
213	CAT-I	D12003	HEPARIN SODIUM INJ IP	5000 I U/ml	5 ml Vial	2088
214	CAT-I	D15034	HOMATROPINE EYE DROPS IP	2%	5 ml	584
215	CAT-I	D04025	HYALURONIDASE INJ IP	1500 IU	1 ml amp	1073
216	CAT-I	D19005	HYDROCHLOROTHIAZIDE TAB IP	25 mg	1 No	374
217	CAT-I	D05002	HYDROCORTISONE SODIUM SUCCINATE INJ IP	100 mg	Vial	1503
218	CAT-I	D08024	HYDROXY CHLOROQUINE TAB IP	200mg	1 No	660
219	CAT-I	D12006	HYDROXY ETHYL STARCH IV INFUSION 6%	130kDa/0.4	500 ml Bottle	935
220	CAT-I	D16013	HYDROXY PROGESTERONE INJ IP	250mg/ ml	1 ml Amp / 2 ml Amp	616
221	CAT-I	D15035	HYDROXY PROPYL METHYL CELLULOSE EYE DROPS	0.30%	10 ml	451
222	CAT-I	D24108C	HYDROXY UREA CAP	500mg	1 No	550
223	CAT-I	D15036	HYDROXYPROPYL METHYL CELLULOSE EYE DROPS	2%	2 ml[PFS]	385
224	CAT-I	D01016	IBUPROFEN TAB IP (FILM COATED)	400 mg	1 No	542
225	CAT-I	D17004	IMIPRAMINE TAB IP	25mg	1 No	526
226	CAT-I	D01031	INDOMETHACIN CAP	25mg	1 No	627
227	CAT-I	D23001	IOHEXOL INJ	350mg/ml	50ml	1837
228	CAT-I	D03013	IPRATROPIUM NEBULISING SOLUTION	250mcg	15 ml	660
229	CAT-I	D22016	IRON SUCROSE INJ USP	(100mg elemental Iron/5ml) or (200mg elemental Iron/5ml)	5ml AMP	963
230	CAT-I	D04022	ISOFLURANE LIQUID	100ml	Bottle	440
231	CAT-I	D13002	ISOSORBIDE DINITRATE TAB IP	10 mg	1 No	835
232	CAT-I	D13049	ISOSORBIDE MONONITRATE TAB IP	20mg	1 No	835
233	CAT-I	D08026	IVERMECTIN TAB	6mg	1 No	990
234	CAT-I	D13051	LABETALOL TAB IP	100mg	1 No	668
235	CAT-I	D13063	LABETALOL INJ	20mg/ml	1ml Amp	620

236	CAT-I	D20015	LACTULOSE SYRUP	667mg/ ml	100 ml	501
237	CAT-I	D07018	LEVETIRACETAM TAB	500mg	1 No	770
238	CAT-I	D02075	LEVOFLOXACIN TAB IP	500mg	1 No	880
239	CAT-I	D04018	LIGNOCAINE 2% WITH ADRENALINE INJ	1:200000	30 ml	1076
240	CAT-I	D04003	LIGNOCAINE HCL GEL IP	2%	30 gm Tube.	702
241	CAT-I	D04004	LIGNOCAINE HCL INJ IP (FOR IV USE)	2% w/v	30 ml Vial	684
242	CAT-I	D02076	LINEZOLID INJ	200mg/100 ml	300 ml bottle	1337
243	CAT-I	D02078	LINEZOLID TAB IP	600mg	1 No	825
244	CAT-I	D14024	LIQUID PARAFFIN IP	100 ml	BOTTLE	363
245	CAT-I	D17025	LITHIUM CARBONATE TAB IP	300 mg	1 No	949
246	CAT-I	D17026	LITHIUM CARBONATE PROLONGED RELEASE TAB IP	400mg	1 No	863
247	CAT-I	D17033	LORAZEPAM TAB IP	2 mg	1 No	1012
248	CAT-I	D13011	LOSARTAN POTASSIUM TAB IP	25 mg	1 No	1211
249	CAT-I	D13053	LOSARTAN POTASSIUM TAB IP	50mg	1 No	1211
250	CAT-I	D12019	LOW MOLECULAR WEIGHT HEPARIN INJ IP	40mg/0.4 ml	VialPFS	7590
251	CAT-I	D16007	MAGNESIUM SULPHATE INJ IP	500mg/ml	2ml Amp	501
252	CAT-I	D14007	MAGNESIUM SULPHATE PASTE BP	500 Gram/ 100gm	Bottle	418
253	CAT-I	D18010	MANNITOL INJ IP	20%w/v	100 ml Bot	1503
254	CAT-I	D16016	MEDROXY PROGESTERONE ACETATE TAB IP	10mg	1 No	715
255	CAT-I	D01014	MEFENAMIC ACID TAB	500 mg	1 No	668
256	CAT-I	D02096	MEROPENAM INJ IP	1gm	Vial	2320
257	CAT-I	D21003	METFORMIN TAB IP	500mg	1 No	668
258	CAT-I	D13039	METHYL DOPA TAB IP	250mg	1 No	715
259	CAT-I	D05012	METHYL PREDNISOLONE SODIUM SUCCINATE INJ USP	500 mg/ 1gm	Vial	1670
260	CAT-I	D05013	METHYL PREDNISOLONE SODIUM SUCCINATE INJ USP	40 mg/ml	1 ml Amp	1002
261	CAT-I	D16004	METHYLERGOMETRIN MALEATE INJ IP	200mcg/ ml	1ml Amp	1169
262	CAT-I	D20005	METOCLOPRAMIDE INJ IP	5mg/ml	2ml Amp	1002
263	CAT-I	D20006	METOCLOPRAMIDE TAB IP	10mg	1 No	584
264	CAT-I	D13033	METOPROLOL TAB IP	50 MG	1 No	501

265	CAT-I	D02025	METRONIDAZOLE INJ IP	5 mg/ml	100ml bottle	1128
266	CAT-I	D02023	METRONIDAZOLE TAB IP	200 mg	1 No	351
267	CAT-I	D02024	METRONIDAZOLE TAB IP	400 mg	1 No	351
268	CAT-I	D02097	METRONIDAZOLE BENZOATE ORAL SUSPENSION IP	200mg/5ml	30ml bottle	200
269	CAT-I	D07011	MIDAZOLAM INJ	1 mg/ml	5 ml Vial	715
270	CAT-I	D16017	MIFEPRISTONE TAB IP	200mg	1 No	770
271	CAT-I	D16024	MISOPROSTOL TAB IP	200mcg	1 No	1520
272	CAT-I	D20013	MIXTURE CARMINATIVE CONCENTRATE(EACH 10ML,CONTAINS:WEAK GINGER TINCTURE BP/IP-0.625ML,AROMATIC SPIRIT OF AMMONIA IP-0.625ML,PEPPERMINT SPIRIT BP-0.25ML,CHLOROFORM IP-0.019ML,SODIUM BICARBONATE IP-0.275 GM, COMPOUND CARDAMOM TINCTURE IP-3.0 ML, AQUA Q.S-10 ML, ALCOHOL CONTENT-20-26% V/V)	500ml	Bottle.	501
273	CAT-I	D15041	MOXIFLOXACIN EYE DROPS IP	0.50%	5 ml	584
274	CAT-I	D14035	MUPIROCIN OINTMENT IP	2%w/w	5gm tube	550
275	CAT-I	D06014	N-ACETYL CYSTEINE INJ	1g	5 ml amp	792
276	CAT-I	D06015	N-ACETYL CYSTEINE TAB	600mg	1 No	668
277	CAT-I	D15042	NATAMYCIN OPTHALMIC SUSPENSION IP	5%w/v	5ml	751
278	CAT-I	D06003	NALOXONE INJ IP	400 mcg/ml	1 ml Amp	1837
279	CAT-I	D16019	NATURAL MICRONISED PROGESTERONE SOFT GELATIN CAP/ SR CAP	200mg	1 no	660
280	CAT-I	D13064	NEBIVOLOL TAB IP	5mg	1 No	1750
281	CAT-I	D15044	NEPAFENAC EYE DROPS	0.1%v/v	5ml	584
282	CAT-I	D04008	NEOSTIGMINE METHYL SULPHATE INJ IP	0.5 mg/ml	1 ml Amp	802
283	CAT-I	D13034	NIFEDIPINE PROLONGED-RELEASE TAB IP	20 mg/ 10 mg	1 No	825
284	CAT-I	D17006	NITRAZEPAM TAB IP	5mg	1 No	584
285	CAT-I	D02080	NITROFURANTOIN TAB IP	100mg	1 No	485
286	CAT-I	D13028	NITROGLYCERIN INJ	25mg/5ml	Amp	1645
287	CAT-I	D29005	NORADRENALINE BITARTRATE INJ	4mg/2ml	2 ml amp	468

288	CAT-I	D16020	NORETHISTERONE TAB IP	5mg	1 No	660
289	CAT-I	D02016	NORFLOXACIN TAB IP	400 mg	1 No	584
290	CAT-I	D15046	OFLOXACIN EAR/EYE DROPS	0.30%	10 ml	660
291	CAT-I	D02018	OFLOXACIN INJ IP	2 mg/ml	100ml bot	1837
292	CAT-I	D02017	OFLOXACIN TAB IP	200 mg	1 No	751
293	CAT-I	D17016	OLANZAPINE TAB IP	10 mg	1 No	726
294	CAT-I	D17020	OLANZAPINE TAB IP	5 mg	1 No	726
295	CAT-I	D20004/12	OMEPRAZOLE CAP IP	20mg	1 No	1503
296	CAT-I	D20014	ONDANSETRON INJ IP	2mg/ml	2 ml Amp	1252
297	CAT-I	D20032	ONDANSETRON TAB IP	4mg	1 No	660
298	CAT-I	D20039	ONDANSETRON ORAL SOLUTION IP	2mg/5ml	30ml bottle	1670
299	CAT-I	D20011/12	ORS POWDER IP	Single dose sachet	20.5 gm Packet	751
300	CAT-I	D09007	OSELTAMIVIR CAP IP	75mg	1 No	880
301	CAT-I	D07019	OXCARBAZEPINE TAB IP	150mg	1 No	584
302	CAT-I	D20018	PANTOPRAZOLE INJ	40mg	10 ml Vial	715
303	CAT-I	D20033	PANTOPRAZOLE TAB IP	40mg	1 No	303
304	CAT-I	D01035	PARACETAMOL INFUSION IP	1gm/100ml	100 ml bottle	668
305	CAT-I	D01009	PARACETAMOL INJ	150mg/2ml	2ml Amp.	668
306	CAT-I	D01003	PARACETAMOL SYRUP/SUSPENSION IP	125mg/5ml	60ml Bottle	751
307	CAT-I	D01002	PARACETAMOL TAB IP	500 mg.	1 No	584
308	CAT-I	D02082	PENICILLIN V TAB IP	250mg	1 No	391
309	CAT-I	D14036	PERMETHRIN CREAM	5%	30gm	660
310	CAT-I	D07003	PHENOBARBITONE SODIUM INJ IP	200mg/ml	1 ml Amp	835
311	CAT-I	D07001	PHENOBARBITONE TAB IP	30 mg	1 No	576
312	CAT-I	D07002	PHENOBARBITONE TAB IP	60 mg	1 No	576
313	CAT-I	D07025	PHENYTOIN ORAL SUSPENSION IP	25mg/ml	200 ml bottle	584
314	CAT-I	D07008	PHENYTOIN SODIUM INJ USP	50mg/ml	2ml amp	1086
315	CAT-I	D07004	PHENYTOIN SODIUM TAB IP	100 mg	1 No	584
316	CAT-I	D12005	PHYTOMENADIONE (VITAMIN K1) INJ	10 mg/ml	1 ml Amp	751
317	CAT-I	D15049	PILOCARPINE NITRATE EYE DROPS IP	2%	5 ml	751

318	CAT-I	D02039	PIPERACILLIN 4GM + TAZOBACTAM 500 MG INJ	4.5gm	Vial	880
319	CAT-I	D02083	PIPERACILLIN+ TAZOBACTAM INJ	2gm + 250mg	Vial	880
320	CAT-I	D18014	POTASSIUM CHLORIDE INJ IP	15% w/v	10ml Amp	743
321	CAT-I	D18015	POTASSIUM CITRATE SOLUTION	Potassium Citrate-1100 mg + Citric Acid-334 mg	200 ml	462
322	CAT-I	D14008	POVIDONE IODINE OINTMENT USP	5%w/w	(25gm Tube) or (10gm Tube)	293
323	CAT-I	D25004	POVIDONE IODINE SCRUB	7.50%	500ml Bottle	226
324	CAT-I	D14011	POVIDONE IODINE SOLUTION IP	5% w/v	500 ml Bottle	317
325	CAT-I	D15051	POVIDONE IODINE SOLUTION IP	5%	5 ml	317
326	CAT-I	D16006	POVIDONE IODINE VAGINAL PESSARIES	200 mg	1 No	317
327	CAT-I	D06004	PRALIDOXIME INJ IP	1 gm	Vial	1086
328	CAT-I	D13056	PRAZOSIN TAB(EXTENDED RELEASE)	5mg	1 No	677
329	CAT-I	D15052	PREDNISOLONE ACETATE EYE/EAR DROPS	1%	5 ml	751
330	CAT-I	D05033	PREDNISOLONE TAB IP	20mg /10mg	1 No	993
331	CAT-I	D05034	PREDNISOLONE TAB IP	5mg	1 No	993
332	CAT-I	D17041	PROCHLORPERAZINE INJ IP	12.5mg/ml	1 ml amp	979
333	CAT-I	D17040	PROCHLORPERAZINE TAB IP	5 mg	1 No	688
334	CAT-I	D05009	PROMETHAZINE INJ IP	25 mg/ml	2ml Amp	710
335	CAT-I	D05015	PROMETHAZINE TAB IP	10 mg	1 No	495
336	CAT-I	D15053	PROPARACAINE HCL OPHTHALMIC SOLUTION	0.50%	5 ml	517
337	CAT-I	D04011	PROPOFOL INJ IP	1% w/v	50ml Vial	1670
338	CAT-I	D13030	PROPRANOLOL TAB	40 MG/ 20 MG	1 No	517
339	CAT-I	D12012	PROTAMINE SULPHATE INJ IP	10 mg/ml	5 ml Amp	1753
340	CAT-I	D17022	QUETIAPINE TAB IP	50 mg	1 No	660
341	CAT-I	D17056	QUETIAPINE TAB IP	100mg	1 No	660
342	CAT-I	D08010	QUININE INJ IP	300 mg/ml	2 ml Amp	935
343	CAT-I	D08037	QUININE TAB IP	300mg	1 No	572
344	CAT-I	D20001	RANITIDINE HCL INJ IP	50mg /2ml	2ml Amp	1253

345	CAT-I	D20002	RANITIDINE HCL TAB IP	150mg	1 No	718
346	CAT-I	D18009	RINGERS LACTATE INJ IP	500ml	Bottle	1670
347	CAT-I	D17017	RISPERIDONE TAB	2 mg	1 No	584
348	CAT-I	D17037	RISPERIDONE TAB	1 mg	1 No	715
349	CAT-I	D03017	SALBUTAMOL INHALATION IP	100 mcg/puff	200 MD	605
350	CAT-I	D03006	SALBUTAMOL NEBULISER SOLUTION BP	5mg/ml.	10ml.	526
351	CAT-I	D03004	SALBUTAMOL SULPHATE TAB IP	4 mg	1 No	751
352	CAT-I	D03024	SALBUTAMOL SYRUP IP	2mg / 5ml	60ml Bottle	501
353	CAT-I	D14025	SALICYLIC ACID OINTMENT	10 % w/w,	20gm tube	605
354	CAT-I	D18016	SALINE INJ	3%	100ml	1045
355	CAT-I	D15011	SALINE NASAL DROPS	0.65 %w/v	15ml Bot	501
356	CAT-I	D01041	SERRATIOPEPTIDASE TAB IP	10mg	1 No	369
357	CAT-I	D17019	SERTRALINE TAB IP	50 mg	1 No	584
358	CAT-I	D14001	SILVER SULPHADIAZINE CREAM IP	1% w/w	100gm	459
359	CAT-I	D14001/12	SILVER SULPHADIAZINE CREAM IP	1% w/w	500gm	459
360	CAT-I	D14023/12	SISOMICIN CREAM	0.1 % w/w	10 gm tube	825
361	CAT-I	D15008	SODIUM BICARBONATE EAR DROPS BPC	10ML	Bottle	501
362	CAT-I	D04012	SODIUM BICARBONATE INJ IP	7.5% w/v	10ml Amp	668
363	CAT-I	D18002	SODIUM CHLORIDE & DEXTROSE INJ IP	0.9%+5%w/v	500ml Bottle	1503
364	CAT-I	D18001	SODIUM CHLORIDE INJ IP	0.9%w/v	500ml Bot	1503
365	CAT-I	D07021	SODIUM VALPROATE INJ	100mg/ml	5 ml vial	990
366	CAT-I	D07023	SODIUM VALPROATE ORAL SOLUTION IP	200mg/5ml	100 ml Bottle	448
367	CAT-I	D07006	SODIUM VALPROATE TAB IP	200 mg	1 No	584
368	CAT-I	D07010	SODIUM VALPROATE TAB IP	500 mg	1 No	584
369	CAT-I	D19003	SPIRONOLACTONE TAB IP	25mg	1 No	459
370	CAT-I	D20036	SUCRALFATE SYRUP	1g/5ml	100 ml bottle	770
371	CAT-I	D25002	SURGICAL SPIRIT IP	500ml	Bottle	501
372	CAT-I	D13061	TELMISARTAN TAB IP	40mg	1 No	668
373	CAT-I	D03001	THEOPHYLLINE AND ETOPHYLLINE INJ	50.6 mg+ 169.4 mg	2 ml Amp.	668

374	CAT-I	D03002	THEOPHYLLINE AND ETOPHYLLINE TAB	23 mg+ 77 mg	1 No	501
375	CAT-I	D04014	THIOPENTONE SODIUM INJ IP	0.5 Gram	Vial	1253
376	CAT-I	D21019	THYROXINE SODIUM TAB IP	100 mcg	1 No	1503
377	CAT-I	D21036	THYROXINE SODIUM TAB IP	50 mcg	1 No	1503
378	CAT-I	D15005	TIMOLOL MALEATE EYE DROPS IP	0.5%w/v	5ml/Bot	584
379	CAT-I	D15059	TOBRAMYCIN EYE OINTMENT	0.30%	5gm	517
380	CAT-I	D15066	TOBRAMYCIN EYE/EAR DROPS	0.3% v/v	5 ml bottle	584
381	CAT-I	D01011	TRAMADOL INJ	50MG/ML	1 ml Amp	1253
382	CAT-I	D01012	TRAMADOL TAB	50MG/ 100MG	1 No	1002
383	CAT-I	D12015	TRANEXAMIC ACID INJ IP	500mg/5ml	5ml amp	935
384	CAT-I	D12014	TRANEXAMIC ACID TAB IP	500 mg	1 No	187
385	CAT-I	D11001	TRIHEXYPHENIDYL TAB IP	2mg	1 No	668
386	CAT-I	D15060	TROPICAMIDE + PHENYLEPHRINE OPHTHALMIC SOLUTION	1% + 2.5%	5 ml	660
387	CAT-I	D14027/12	TURPENTINE LINIMENT IP	50 ml	bottle	330
388	CAT-I	D20037	URSODEOXYCHOLIC ACID TAB IP	300mg	1 No	880
389	CAT-I	D02027	VANCOMYCIN HYDROCHLORIDE INJ IP	500mg	Vial	1837
390	CAT-I	D04020	VECURONIUM BROMIDE INJ IP	4mg	Vial	1518
391	CAT-I	D04021	VECURONIUM BROMIDE INJ IP	10mg	Vial	1518
392	CAT-I	D13007/12	VERAPAMIL TAB IP	40mg	1 No	584
393	CAT-I	D22002/12	VITAMIN B COMPLEX (STRONG) TAB	Each Tablet Containing Nictonamide IP 20mg, Pyridoxine HCL IP 2 mg, Riboflavin IP 2 mg, Thiamine HCL IP 5 mg	1 No	501
394	CAT-I	D12001/12	VITAMIN B12/ CYANOCOBALAMIN INJ IP	100MCG/ml	2ml amp	810
395	CAT-I	D22020	VITAMIN C TAB IP	500mg	1 No	220

396	CAT-I	D22004/12	VITAMIN MULTI TAB(FILM COATED)	Each Tablet Containing Vitamin A-2500 iuVitamin-D 200 iuVitamin-B1 2mgVitamin-B2 2mg Vitamin B6 0.5 mgCalciumPantothenate-1mgNiacinamide-25mgVitamin-C 50mgFolic Acid-0.2mg	1 No	668
397	CAT-I	D21038	VOGLIBOSE TAB IP	0.2mg	1 No	990
398	CAT-I	D12013/12	WARFARIN SODIUM TAB IP	2mg / 1mg	1 No	605
399	CAT-I	D12021	WARFARIN SODIUM TAB IP	5mg	1 No	605
400	CAT-I	D18011	WATER FOR INJECTION IP	10 ml	Amp	1503
401	CAT-I	D14040	WHITE SOFT PARAFFIN IP	50gm	Bottle	418
402	CAT-I	D14005	WHITFIELDS OINTMENT IP	15 gm	Tube	418
403	CAT-I	D15009	XYLOMETAZOLINE NASAL DROPS IP	0.1% w/v	10 ml Bottle	501
404	CAT-I	D17059	ZOLPIDEM TAB IP	10mg	1 No	990
						0
405	CAT-III	S27009	BLOOD ADMINISTRATION SET WITH MICROAGREGATE FILTER	Ml	1 No	1470
406	CAT-III	S27014	BP BLADE	SIZE -10	1 NO	1253
407	CAT-III	S27015	BP BLADE	SIZE -11	1 NO	1253
408	CAT-III	S27016	BP BLADE	SIZE -15	1 NO	1253
409	CAT-III	S27017	BP BLADE	SIZE -20	1 NO	1253
410	CAT-III	S27019	BP BLADE	SIZE -22	1 NO	1253
411	CAT-III	S27026	DISPOSABLE NEEDLE	20 G	1 No	1503
412	CAT-III	S27028	DISPOSABLE NEEDLE	22 G	1 No	1503
413	CAT-III	S27029	DISPOSABLE NEEDLE	23 G	1 No	1503
414	CAT-III	S27030	DISPOSABLE NEEDLE	24 G	1 No	1503
415	CAT-III	S27239	DISPOSABLE SYRINGE WITH FIXED NEEDLE 29 G (1ML GRADUATED)	1ml	1 NO	2157
416	CAT-III	S27031	DISPOSABLE SYRINGE WITHOUT NEEDLE	2 Cc	1 No	1253
417	CAT-III	S27032	DISPOSABLE SYRINGE WITHOUT NEEDLE	5 Cc	1 No	1253
418	CAT-III	S27033	DISPOSABLE SYRINGE WITHOUT NEEDLE	10 Cc	1 No	1253
419	CAT-III	S27039	DISPOSABLE THREE WAY STOPCOCK	1 Unit	1 No	1503
420	CAT-III	S27045	ENDOTRACHEAL TUBE 2.5	1 Unit	1 No	1503

421	CAT-III	S27046	ENDOTRACHEAL TUBE 3.0	1 Unit	1 No	1503
422	CAT-III	S27047	ENDOTRACHEAL TUBE 3.5	1 Unit	1 No	1503
423	CAT-III	S27048	ENDOTRACHEAL TUBE 4.0	1 Unit	1 No	1503
424	CAT-III	S27049	ENDOTRACHEAL TUBE 4.5	1 Unit	1 No	1503
425	CAT-III	S27050	ENDOTRACHEAL TUBE 5.0	1 Unit	1 No	1503
426	CAT-III	S27051	ENDOTRACHEAL TUBE 5.5	1 Unit	1 No	1503
427	CAT-III	S27054	ENDOTRACHEAL TUBE 5.5 WITH CUFF	1 Unit	1 No	1503
428	CAT-III	S27052	ENDOTRACHEAL TUBE 6.0	1 Unit	1 No	1503
429	CAT-III	S27055	ENDOTRACHEAL TUBE 6.0 WITH CUFF	1 Unit	1 No	1503
430	CAT-III	S27053	ENDOTRACHEAL TUBE 6.5	1 Unit	1 No	1503
431	CAT-III	S27056	ENDOTRACHEAL TUBE 6.5 WITH CUFF	1 Unit	1 No	1503
432	CAT-III	S27057	ENDOTRACHEAL TUBE 7.0 WITH CUFF	1 Unit	1 No	1503
433	CAT-III	S27058	ENDOTRACHEAL TUBE 7.5 WITH CUFF	1 Unit	1 No	1503
434	CAT-III	S27059	ENDOTRACHEAL TUBE 8.0 WITH CUFF	1 Unit	1 No	1503
435	CAT-III	S27060	ENDOTRACHEAL TUBE 8.5 WITH CUFF	1 Unit	1 No	1503
436	CAT-III	S27061	ENDOTRACHEAL TUBE 9.0 WITH CUFF	1 Unit	1 No	1503
437	CAT-III	S27222	EPIDURAL SET WITH LOR SYRINGE & FILTER	18 G	1 No	1320
438	CAT-III	S27062	FOLLEYS CATHETER	SIZE 12 F X 10 ML	1 No	1503
439	CAT-III	S27063	FOLLEYS CATHETER	SIZE 16F X 30 ML	1 No	1503
440	CAT-III	S27064	FOLLEYS CATHETER	SIZE 18 F X 30 ML	1 No	1503
441	CAT-III	S27067	FOLLEYS CATHETER	SIZE 10 F X 10 ML	1 No	1503
442	CAT-III	S27193	FOLLEYS CATHETER	SIZE 14 F X 30 ML	1 No	1366
443	CAT-III	S27038	I.V. CANNULA	24 G	1 No	1503
444	CAT-III	S27034	I.V. CANNULA WITH INJECTION PORT	16 G	1 No	1503
445	CAT-III	S27035	I.V. CANNULA WITH INJECTION PORT	18 G	1 No	1503
446	CAT-III	S27036	I.V. CANNULA WITH INJECTION PORT	20 G	1 No	1503
447	CAT-III	S27037	I.V. CANNULA WITH INJECTION PORT	22 G	1 No	1503
448	CAT-III	S27246	I.V. SET WITH 22G NEEDLE	1 Unit	1 No	1503
449	CAT-III	S27069	INFANT FEEDING TUBE	SIZE 4F	1 No	1503

450	CAT-III	S27070	INFANT FEEDING TUBE	SIZE 10F	1 No	1503
451	CAT-III	S27071	INFANT FEEDING TUBE	SIZE 5F	1 No	1503
452	CAT-III	S27072	INFANT FEEDING TUBE	SIZE 6F	1 No	1503
453	CAT-III	S27073	INFANT FEEDING TUBE	SIZE 8F	1 No	1503
454	CAT-III	S27221	NELATON CATHETER	SIZE 12	1 No	1320
455	CAT-III	S27076	RYLES TUBE	SIZE 10 F	1 No	1503
456	CAT-III	S27077	RYLES TUBE	SIZE 12 F	1 No	1503
457	CAT-III	S27079	RYLES TUBE	SIZE 16 F	1 No	1503
458	CAT-III	S27250	SICS BLADE (CRESANT)	2.5mm/2.6mm angeled level up	1No	1139
459	CAT-III	S27251	SICS BLADE (KERATOME)	2.8mm angeled level up	1No	1139
460	CAT-III	S27252	SICS BLADE (SIDE PORT)	15° STRAIGHT LANCE TIP	1No	1139
461	CAT-III	S27041	SPINAL NEEDLE	SIZE 23 G	1 No	1503
462	CAT-III	S27238	SPINAL NEEDLE	SIZE 25 G	1 No	1503
463	CAT-III	S27089	SUCTION CATHETER	SIZE – 10	1 No	1503
464	CAT-III	S27090	SUCTION CATHETER	SIZE – 12	1 No	1503
465	CAT-III	S27091	SUCTION CATHETER	SIZE – 14	1 No	1503
466	CAT-III	S27092	SUCTION CATHETER	SIZE – 6	1 No	1503
467	CAT-III	S27093	SUCTION CATHETER	SIZE – 8	1 No	1503
468	CAT-III	S27233	UMBILICAL CORD CLAMP	-	1 No	1253
469	CAT-III	S27095	URINE COLLECTING BAG WITH VALVE OUTLET	2 LITRE	1 No	2505
470	CAT-III	S27068	VACUSUCK SET (MOULDED TRANSPARENT HAVING NO JOINTS ON THE SURFACE OF THE TUBING)	2.5 M	1 No	1503
471	CAT-IV	S27010	BLOOD COLLECTION SINGLE BAG	350 ML	1 NO	1320
472	CAT-IV	D26006	MALARIA ANTIGEN DETECTING CARD	1TEST	1 No	1670
473	CAT-V	S27231/12	ABSORBANT COTTON GAUZE SCH.F(II)	100 CmX 20 M	Packet	584
474	CAT-V	S27007	ABSORBANT COTTON WOOL IP	500gm Net	Packet	501
475	CAT-V	S27002	ADHESIVE TAPE U.S.P	10 cm X 5 mtr	Roll	1002
476	CAT-V	S27099	DISPOSABLE SURGEONS CAP - FEMALE	1 Unit	1 No	1002
477	CAT-V	S27098	DISPOSABLE SURGEONS CAP - MALE	1 Unit	1 No	1002
478	CAT-V	S27100	DISPOSABLE SURGEONS MASK (DOUBLE LAYER WITH TYING STRAP)	1 Unit	1 No	1002

479	CAT-V	S27194	ECG GEL	250 GM	BOTTLE	1265
480	CAT-V	S27085	GLOVES SURGICAL RUBBER (ISI)-Non Sterile	SIZE 6”	Pair	1503
481	CAT-V	S27086	GLOVES SURGICAL RUBBER (ISI)-Non Sterile	SIZE 6.5”	Pair	1503
482	CAT-V	S27087	GLOVES SURGICAL RUBBER (ISI)-Non Sterile	SIZE 7”	Pair	1503
483	CAT-V	S27088	GLOVES SURGICAL RUBBER (ISI)-Non Sterile	SIZE 7.5”	Pair	1503
484	CAT-V	S27196	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 6"	Pair	1503
485	CAT-V	S27197	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 6.5"	Pair	1503
486	CAT-V	S27198	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 7"	Pair	1503
487	CAT-V	S27199	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 7.5"	Pair	1503
488	CAT-V	S27003	HYPO ALLERGIC ACRYLIC PAPER TAPE	2.5cm X 9.1 mtr	Roll	993
489	CAT-V	S27230	PLASTER OF PARIS BANDAGE BP	10 cm X 2.7 mtr	Roll	668
490	CAT-V	S27001	PLASTER OF PARIS BANDAGES B.P	15 cm X 2.7 mtr	ROLL	668
491	CAT-V	S27075	RUBBER SHEET MACKINTHOSH	1 mtr	1 No	1503
492	CAT-VI	D25012	BLACK DISINFECTANT FLUID (GRIII RWC 5-7) BIS LOTION	5 Litre	Can	584
493	CAT-VI	D25011	BLEACHING POWDER	30%	1 kg Packet	334
494	CAT-VI	D25010	CHLORHEXIDINE GLUCONATE 2.5% V/V + ETHYL ALCOHOL 70% V/V SOLUTION	200 ml	Bottle	835
495	CAT-VI	D25006	CHLOROXYLENOL SOLUTION IP	5%	5 Lit Can	584
496	CAT-VI	D25014	FORMALDEHYDE SOLUTION IP	37% w/v	450 ml Bottle	418
497	CAT-VI	D25007	GLUTERALDEHYDE SOLUTION(WITHOUT SURFACTANT)	2%	5 Litre Can	501
498	CAT-VI	D25003/12	HYDROGEN PEROXIDE SOLUTION IP	20 Vol	1ltr. Bottle	317
499	CAT-VI	D25008	ORTHO-PHTHALALDEHYDE LOTION	0.55%	5 Ltr Can	501
500	CAT-VI	D25013	WASHING SODA	1 Kg	Packet	501
501	CAT-VII	S27505	BLACK SILK 5-0 1/2 CIRCLE ,TAPER CUT NEEDLE 17MM , 70- 90 CM	1 Foil	1 No	1253
502	CAT-VII	S27508/12	BRAIDED POLYGLYCOLIC ACID SUTURE 3-0, 40- 50CM, 3/8 CIRCLE CUTTING 12MM NEEDLE	1 Foil	1 No	1253

503	CAT-VII	S27509	BRAIDED POLYGLYCOLIC ACID SUTURE 5-0, 45CM, 3/8 CIRCLE REVERSE CUTTING 12MM NEEDLE	1 Foil	1 No	1253
504	CAT-VII	S27510	BRAIDED POLYGLYCOLIC ACID SUTURE 6-0, 45CM, 3/8 CIRCLE REVERSE CUTTING 12MM NEEDLE	1 Foil	1 No	1253
505	CAT-VII	S27517	CATGUT NO.1/0 RB 34-40 MM NEEDLE, 70-90 CM	1 Foil	1 No	1253
506	CAT-VII	S27519	MONOFILAMENT POLYAMIDE 10-0, 1/2 CIRCLE Micropoint Spatulated DOUBLE NEEDLE 6MM,30-40 CM	1 Foil	1 No	1253
507	CAT-VII	S27520/12	MONOFILAMENT POLYAMIDE 2-0,30-36MM, 3/8 CIRCLE CUTTING NEEDLE, 70-90CM	1 Foil	1 No	1253
508	CAT-VII	S27523/12	MONOFILAMENT POLYAMIDE 3-0,30-36MM,3/8 CIRCLE CUTTING NEEDLE,70-90CM	1 Foil	1 No	1253
509	CAT-VII	S27524/12	MONOFILAMENT Black POLYAMIDE 8/0, 3/8 CIRCLE REVERSE CUTTING MICRO POINT SPatulated 8MM, 30-40CM	1 Foil	1 No	1253
510	CAT-VII	S27525	MONOFILAMENT POLYPROPYLENE BLUE 1, 70-90CM 1/2 CRB (HEAVY) 40MM	1 Foil	1 No	1253
511	CAT-VII	S27526	MONOFILAMENT POLYPROPYLENE BLUE 1-0, 70-90CM 1/2 CRB 30MM	1 Foil	1 No	1253
512	CAT-VII	S27533	POLYDIOXANONE OF SIZE 1 WITH ½ CIRCLE RB, 45- 50MM HEAVY NEEDLE SUTURE LENGTH 1.5 M,FOR SHEATH CLOSURE	1 Foil	1 No	1253
513	CAT-VII	S27535	POLYGLACTIN 910 4-0,ROUND BODY NEEDLE 3/8 CIRCLE , 20MM,70-90 CM	1 Foil	1 No	1253
514	CAT-VII	S27536	POLYGLACTIN 910 OF SIZE 1,1/2 CIRCLE ROUND BODY NEEDLE,35-40 MM ,70-90 CM	1 Foil	1 No	1253
515	CAT-VII	S27537	POLYGLACTIN 910 OF SIZE 1-0,1/2 CIRCLE ROUND BODY 30- 36MM,70-90 CM	1 Foil	1 No	1253
516	CAT-VII	S27538	POLYGLACTIN 910,SIZE 2-0,1/2 CRB,30MM NEEDLE ,70-90CM	1 Foil	1 No	1253
517	CAT-VII	S27539	POLYGLACTIN 910,SIZE 3-0,1/2 CRB,26-30MM NEEDLE ,70-90CM	1 Foil	1 No	1253
518	CAT-VII	S27547	POLYGLYCOLIC ACID SIZE 6/0 , 3/8 REVERSE CUTTING, 8MM,DOUBLE NEEDLE,70-90 CM	1 Foil	1 No	1253

519	CAT-VII	S27549	POLYPROPYLENE 2-0, 1/2 CRB 26-30MM NEEDLE ,70-90 CM	1 Foil	1 No	1253
520	CAT-VII	S27550	POLYPROPYLENE 3-0, 1/2 CRB 24-26MM NEEDLE, 70-90 CM	1 Foil	1 No	1253
521	CAT-VII	S27553	POLYPROPYLENE 5-0, 3/8 ROUND BODY 12MM NEEDLE ,70-90 CM	1 Foil	1 No	1253
522	CAT-VII	S27555	Monofilament blue POLYPROPYLENE 6-0, 3/8 CIRCLE TAPER CUT, DOUBLE ARMED NEEDLE,13MM,70-90 CM	1 Foil	1 No	1253
523	CAT-VII	S27557	POLYPROPYLENE MESH 0.02 THICKNESS WITH 1.9KG BURST STRENGTH PER SQUARE CM HERNIA REPAIR	15x15 Cm	1 No	1253
524	CAT-VII	S27559/12	POLYPROPYLENE MESH 0.02 THICKNESS WITH 1.9KG BURST STRENGTH PER SQUARE CM HERNIA REPAIR	7X15 cm	1 No	1253
525	CAT-VII	S27561/12	SURGICAL SILK 2-0, 1/2 CIRCLE CUTTING NEEDLE 30MM,70-90 CM	1 Foil	1 No	1253
526	CAT-VII	S27564	SURGICAL SILK 4-0, 1/2 CIRCLE TAPERCUT NEEDLE 17MM,70-90 CM	1 Foil	1 No	1253
527	CAT-VII	S27565	SUTURE PACK SILK No. 1, 2X70-90 CM	1 Foil	1 No	1253
528	CAT-VII	S27568	SUTURE PACK SILK No. 2-0, 2X70-90 CM	1 Foil	1 No	1253

APPENDIX I-B

List of items for which lab rates for testing are to be offered by the Laboratory

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
1	ACD	D24059C	BENDAMUSTINE INJ	100mg	Vial	
2	ACD	D24162C	EVEROLIMUS TAB	5mg	1 No	
3	ACD	D24163C	LENALIDOMIDE CAP	5mg	1 No	
4	CAT-I	D02092	AMOXYCILLIN + POTASSIUM CLAVULANATE DROPS	80mg + 11.4mg	10ml bottle	
5	CAT-I	D15019	BIMATOPROST EYE DROPS	0.03%	3 ml	
6	CAT-I	D03025	BUDESONIDE NEBULISING SOLUTION	0.5mg/ml	2ml respules	
7	CAT-I	D22025	CALCIUM CARBONATE +VITAMIN D3 SUSPENSION	200mg + 200IU	100ml bottle	
8	CAT-I	D12029	CALCIUM DOBESILATE CAP	500mg	1 No	
9	CAT-I	D02095	CEFUROXIME AXETIL SYRUP	125mg/5ml	30ml bottle	
10	CAT-I	D20039	DOXYLAMINE SUCCINATE TAB USP	5mg	1 No	
11	CAT-I	D07027	LEVITERACETAM INJ	100mg/ml	Amp	
12	CAT-I	D20040	SODIUM PHOSPHATE ENEMA	Sodium Dihydrogen Phosphate Dihydrate IP 10%w/v + Disodium Hydrogen Phosphate Dodecahydrate IP 8%w/v	100ml	
13	CAT-I	D22026	VITAMIN D3 DROPS IP	400IU/ml	15ml	
14	CAT-III	S27254	DISPOSABLE NEEDLE	26 G	1 No	
15	CAT-III	S27247	DISPOSABLE CVP CATHETER DOUBLE LUMEN (SELDINGER TECHNIQUE)	5F	1No	
16	CAT-III	S27248	DISPOSABLE CVP CATHETER DOUBLE LUMEN (SELDINGER TECHNIQUE)	7F	1No	
17	CAT-IV	D26002	ANTI A MONOCLONAL IgM TITRE VALUE 512 (MINIMUM) SOLUTION	10ml	Bottle	
18	CAT-IV	D26003	ANTI AB MONOCLONAL IgM TITRE VALUE 512 (MINIMUM)SOLUTION	10 ML	Bottle	
19	CAT-IV	D26004	ANTI B MONOCLONAL IgM TITRE VALUE 512 (MINIMUM) SOLUTION	10ml	Bottle	
20	CAT-IV	D26005	ANTI D MONOCLONAL IgM TITRE VALUE 512 SOLUTION	10ML	Bottle	
21	CAT-IV	D26030	ANTI HUMAN GLOBULIN SERUM (COOMBS SERUM) POLY SPECIFIC (IgG + C3d)	5ml	Vial	

22	CAT-IV	S27253	BLOOD COLLECTION TRIPLE BAG	Sterile collapsible non-vented bags made up of DEHP plasticized PVC. Primary bag - 350ml,with CPDA 1 (49ml) First Satelite bag - 300ml Second Satelite bag – 300ml for platelet storage for 5 days Slits on both sides of the bags. Flexible non-kinking transparent tubings. Needle -16G straight sharp regular margins ultrathin walled and bevelled tips.	1 No	
23	CAT-IV	D26014	DENGUE IgM CAPTURE ELISA (1,2,3,4) KIT	1TEST	1 No	
24	CAT-IV	D26026	DENGUE LATEX AGGLUTINATION TEST KIT(RAPID METHOD)	1TEST	1 No	
25	CAT-IV	D26024	FOURTH GENERATION ELISA KIT FOR DETECTION OF P24 ANTIGEN AND ANTIBODY TO HIV 1&2	1TEST	1No	
26	CAT-IV	D26023	HEPATITIS B SURFACE ANTIGEN SCREENING KIT-EIA VISUAL ASSAY TEST	1 Test	1 No	
27	CAT-IV	D26017	HEPATITIS C ANTIBODY SCREENING-ELISA TEST KIT	1TEST	1No	
28	CAT-IV	D26016	HEPATITS C ANTIBODY SCREENING KIT - EIA VISUAL ASSAY(RAPID METHOD)	1TEST	1 No	
29	CAT-IV	D26019	HIV 1 & 2 ANTIBODY SCREENING EIA VISUAL ASSAY(RAPID METHOD)	1TEST	1 No	
30	CAT-IV	D26031	RPR CARD TEST FOR SYPHILIS	1 Test	1No	
31	CAT-V	S27219	ECG ELECTRODES	NULL	1 No	
32	CAT-VII	S27529	POLIGLECAPRONE 25, UNDYED, SIZE 3/0 WITH 3/8 CIRCLE	1 Foil	1 No	
33	CAT-VII	S27531	POLIGLECAPRONE 25, UNDYED, SIZE 5/0 WITH 3/8 CIRCLE CUTTING / REVERSE CUTTING NEEDLE 12-15 MM,70-90 CM	1 Foil	1 No	
34	CAT-VIII	X01012	X- RAY DEVELOPER LIQUID	19.5/Lit.	Packet	
35	CAT-VIII	X01010	X- RAY DEVELOPER POWDER	Powder to make 22.5 litres	Pkts	
36	CAT-VIII	X01011	X- RAY FIXER LIQUID	19.5/Lit.	Packet	
37	CAT-VIII	X01009	X- RAY FIXER POWDER	Powder to make 22.5 litres	Pkts	
38	CAT-VIII	X01013	X-RAY FILM DEVELOPER	Powder To Make 13.5 Litres	Packet	

39	CAT-VIII	X01014	X-RAY FILM FIXER	Powder To Make 13.5 Litres	1 No	
40	CAT-VIII	X01001	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	8" X 10"	Pkts of 50 nos	
41	CAT-VIII	X01002	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	10" X 12"	Pkts of 50 nos	
42	CAT-VIII	X01003	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	12" X 15"	Pkts of 50 nos	
43	CAT-VIII	X01006	X-RAY FILM-INTRA ORAL OCCLUSAL	SIZE-4(57X76mm)EKTA SPEED	Pks of 25 Films	
44	CAT-VIII	X01004	X-RAY FILM-INTRA ORAL PERIAPICAL	SIZE-2(31X41mm)EKTA SPEED IN POLY SOFT PACKET	Pks of 150 Films	
45	CAT-VIII	X01005	X-RAY FILM-INTRA ORAL PERIAPICAL	SIZE-0(22X35mm)EKTA SPEED IN POLY SOFT PACKET	Pks of 100 Films	